Fredrick B. Hagemeister, M.D.

Peer-Reviewed Articles

1. Akkad, N, Feng, L, Westin, JR, Hagemeister, FB, Lee, HJ, Fayad, LE, Ahmed, S, Nair, R, Rodriguez, MA, Strati, P, Chihara, D, Flowers, CR, Claret, LC, Ibanez, K, Wang, L, Fowler, N, Henderson, J, Davis, RE, Neelapu, SS, Green, M, Nastoupil, L. A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma. Blood Advances 9(17):4396-4404, 2025. e-Pub 2025. PMID: 40517417.
2. Chihara D, Steiner RE, Nair R, Feng L, Ahmed S, Strati P, Malpica L, Griffith DP, Mathew SA, Montinez W, Masand G, Samaniego F, Rodriguez MA, Hagemeister FB, Fayad LE, Iyer SP, Nastoupil LJ, Neelapu SS, Flowers CR, Westin JR. Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas. Blood Adv 9(7):1485-1491, 2025. e-Pub 2025. PMID: 39908461.
3. Gurumurthi A, Chin CK, Feng L, Fowler NH, Strati P, Hagemeister FB, Fayad LE, Westin JR, Obi C, Arafat J, Nair R, Steiner RE, Neelapu SS, Flowers CR, Nastoupil LJ. Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial. EClinicalMedicine 74:102747, 2024. e-Pub 2024. PMID: 39161543.
4. Gordon MJ, Feng L, Strati P, Lee HJ, Hagemeister FB, Westin JR, Samaniego F, Marques-Piubelli ML, Vega Vazquez F, Parra Cuentas ER, Solis-Soto LM, Ma W, Wang J, Claret L, Averill B, Ibanez K, Fayad LE, Flowers CR, Green MR, Davis RE, Neelapu SS, Fowler NH, Nastoupil LJ. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study. Cancer 130(6):876-885, 2024. e-Pub 2024. PMID: 37985359.
5. Xu-Monette ZY, Li Y, Snyder T, Yu T, Lu T, Tzankov A, Visco C, Bhagat G, Qian W, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Wang Y, Go H, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Fan X, van Krieken JH, Piris MA, Winter JN, Au Q, Kirsch I, Zhang M, Shaughnessy J, Xu B, Young KH. Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL. Clin Cancer Res 29(23):4808-4821, 2023. e-Pub 2023. PMID: 37728879.
6. Strati P, Li X, Deng Q, Marques-Piubelli ML, Henderson J, Watson G, Deaton L, Cain T, Yang H, Ravanmehr V, Fayad LE, Iyer SP, Nastoupil LJ, Hagemeister FB, Parra ER, Saini N, Takahashi K, Fowler NH, Westin JR, Steiner RE, Nair R, Flowers CR, Wang L, Ahmed S, Al-Atrash G, Vega F, Neelapu SS, Green MR. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells. Cell Rep Med 4(8):101158, 2023. e-Pub 2023. PMID: 37586321.
7. Cherng HJ, Alig S, Oki Y, Nastoupil LJ, Fayad LE, Neelapu SS, Turturro F, Hagemeister FB, Craig A, Macaulay C, Rodriguez MA, Lee HJJ, McDonnell T, Flowers CR, Vega F, Green MR, Feng L, Kurtz DM, Alizadeh AA, Davis RE, Westin JR. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Adv 7(7):1137-1145, 2023. e-Pub 2022. PMID: 36375046.
8. Li Y, Xu-Monette ZY, Abramson J, Sohani AR, Bhagat G, Tzankov A, Visco C, Zhang S, Dybkaer K, Pan Z, Xu M, Tam W, Zu Y, Hsi ED, Hagemeister FB, Go H, van Krieken JH, Winter JN, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Wang Y, Zhang M, Young KH. EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential. Blood Adv 7(7):1308-1311, 2023. e-Pub 2023. PMID: 36399513.
9. Steiner RE, Parra ER, Vega F, Feng L, Westin JR, Neelapu SS, Strati P, Green MR, Flowers CR, Solis LM, Wistuba II, Ahmed S, Nair R, Hagemeister FB, Noorani M, Marques-Piubelli ML. PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma. Exp Hematol Oncol 12(1):32, 2023. e-Pub 2023. PMID: 36941707.
10. Westin J, Davis RE, Feng L, Hagemeister F, Steiner R, Lee HJ, Fayad L, Nastoupil L, Ahmed S, Rodriguez A, Fanale M, Samaniego F, Iyer SP, Nair R, Oki Y, Fowler N, Wang M, Ma MCJ, Vega F, McDonnell T, Pinnix C, Griffith D, Lu Y, Tewari S, Sun R, Scott DW, Flowers CR, Neelapu S, Green MR. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J Clin Oncol 41(4):JCO2200597, 2023. e-Pub 2022. PMID: 35952327.
11. Cherng HJ, Xu G, Feng L, Steiner R, Fayad L, Strati P, Nair R, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Rodriguez M, Wang M, Hagemeister F, Pinnix CC, Ramdial J, Srour S, Nieto Y, Rezvani K, Champlin R, Kebriaei P, Westin J, Macapinlac HA, Shpall E, Ahmed S. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Br J Haematol 200(1):35-44, 2023. e-Pub 2023. PMID: 36068929.
12. Han G, Deng Q, Marques-Piubelli ML, Dai E, Dang M, Ma MCJ, Li X, Yang H, Henderson J, Kudryashova O, Meerson M, Isaev S, Kotlov N, Nomie KJ, Bagaev A, Parra ER, Solis Soto LM, Parmar S, Hagemeister FB, Ahmed S, Iyer SP, Samaniego F, Steiner R, Fayad L, Lee H, Fowler NH, Flowers CR, Strati P, Westin JR, Neelapu SS, Nastoupil LJ, Vega F, Wang L, Green MR. Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression. Blood Cancer Discov 3(5):428-443, 2022. e-Pub 2022. PMID: 35687817.
13. Cherng HJ, Sun R, Sugg B, Irwin R, Yang H, Le CC, Deng Q, Fayad L, Fowler NH, Parmar S, Steiner R, Hagemeister F, Nair R, Lee HJ, Rodriguez M, Samaniego F, Iyer SP, Flowers CR, Wang L, Nastoupil LJ, Neelapu SS, Ahmed S, Strati P, Green MR, Westin J. Risk assessment with low pass whole genome sequencing of cell free DNA before CD19 CAR T-cells for large B-cell lymphoma. Blood 140(5):504-515, 2022. e-Pub 2022. PMID: 35512184.
14. Marques-Piubelli ML, Parra ER, Feng L, Soto LS, Gallardo M, Gouni S, Samaniego F, Noorani M, Hagemeister FB, Westin JR, Lee HJ, Rodriguez MA, Neelapu SS, Gunther JR, Fowler NH, Flowers CR, Wistuba II, Nastoupil LJ, Vega F, Strati P. SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab. Blood Adv 6(11):3286-3293, 2022. e-Pub 2022. PMID: 35359004.
15. Xu-Monette ZY, Wei L, Fang X, Au Q, Nunns H, Nagy M, Tzankov A, Zhu F, Visco C, Bhagat G, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Sun X, Han X, Go H, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, van Krieken JH, Piris MA, Winter JN, Li Y, Xu B, Albitar M, You H, Young KH. Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. Clin Cancer Res 28(5):972-983, 2022. e-Pub 2022. PMID: 34980601.
16. Wang ML, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L, Ok CY, Kanagal-Shamanna R, Hill HA, Yao Y, Hagemeister FB, Westin JR, Fowler N, Samaniego F, Steiner R, Nair R, Iyer SP, Navsaria L, Badillo M, Research Group MC, Feng L, Xuelin H, Nogueras Gonzalez GM, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Lin P, Wang SA, Jorgensen J, Yin CC, Li S, Patel KP, Vega F, Medeiros LJ, Flowers CR, Wang L. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol 23(3):406-415, 2022. e-Pub 2022. PMID: 35074072.
17. Albitar M, Zhang H, Goy A, Xu-Monette ZY, Bhagat G, Visco C, Tzankov A, Fang X, Zhu F, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, van Krieken JH, Piris MA, Winter JN, Li Y, Xu B, Young KH. Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. Blood Cancer J 12(2):25, 2022. e-Pub 2022. PMID: 35105854.
18. Jain P, Zhao S, Lee HJ, Hill HA, Ok CY, Kanagal-Shamanna R, Hagemeister FB, Fowler N, Fayad L, Yao Y, Liu Y, Moghrabi OB, Navsaria L, Feng L, Nogueras Gonzalez GM, Xu G, Thirumurthi S, Santos D, Iliescu C, Tang G, Medeiros LJ, Vega F, Avellaneda M, Badillo M, Flowers CR, Wang L, Wang ML. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. J Clin Oncol 40(2):202-212, 2022. e-Pub 2022. PMID: 34797699.
19. Cherng HJ, Chuang HH, Steiner R, Fayad L, Strati P, Nair R, Hagemeister F, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Samaniego F, Rodriguez M, Macapinlac HA, Feng L, Westin J. A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma 63(1):1-10, 2022. e-Pub 2022. PMID: 34435552.
20. Nastoupil LJ, Neelapu SS, Davis RE, Samaniego F, Fowler NH, Westin J, Lee HJ, Wang M, Hagemeister F, Cecil ARL, Dow J, Haque K, Silva FA, Whale A, Lensun L, Bone EA, McElwaine-Johnn H, Beer PA. Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma. Leuk Lymphoma 62(14):1-11, 2021. e-Pub 2021. PMID: 34365878.
21. Strati P, Varma A, Adkins S, Nastoupil LJ, Westin J, Hagemeister FB, Fowler NH, Lee HJ, Fayad LE, Samaniego F, Ahmed S, Chen Y, Horowitz S, Arafat S, Johncy S, Kebriaei P, Mulanovich VE, Ariza Heredia E, Neelapu SS. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica 106(10):2667-2672, 2021. e-Pub 2021. PMID: 32732355.
22. Wang Y, Gali VL, Xu-Monette ZY, Sano D, Thomas SK, Weber DM, Zhu F, Fang X, Deng M, Zhang M, Hagemeister FB, Li Y, Orlowski RZ, Lee HC, Young KH. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia. Neoplasia 23(4):361-374, 2021. e-Pub 2021. PMID: 33735664.
23. Strati P, Jain P, Johnson RJ, Forbes S, Feng L, Samaniego F, Rodriguez MA, Fayad LE, Hagemeister F, Westin J, Wang M, Neelapu SS, Nastoupil LJ, Fowler NH. Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma. Blood 137(8):1124-1129, 2021. e-Pub 2021. PMID: 32932518.
24. Deng M, Xu-Monette ZY, Pham LV, Wang X, Tzankov A, Fang X, Zhu F, Visco C, Bhagat G, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, You H, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Hagemeister F, van Krieken JH, Piris MA, Winter JN, Li Y, Xu B, Liu P, Young KH. Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. Mol Cancer Res 19(2):249-260, 2021. e-Pub 2021. PMID: 33154093.
25. Ciurea SO, Kongtim P, Srour S, Saini N, Im J, Ramdial J, Khouri I, Anderlini P, Popat U, Hosing C, Champlin RE, Lee HJ, Fayad LE, Hagemeister FB, Bica AM, Lipan L, Craciun O, Jercan CG, Tanase A, Colita A. Can we cure refractory Hodgkin's lymphoma with transplantation?. Bone Marrow Transplant 56(1):278-281, 2021. e-Pub 2021. PMID: 32636464.
26. Samaniego F, McLaughlin P, Neelapu SS, Feng L, Fanale M, Nastoupil L, Rodriguez MA, Pro B, Taylor E, Hagemeister FB, Fowler N. Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma. Leuk Lymphoma 62(1):1-10, 2021. e-Pub 2021. PMID: 32924687.
27. You H, Xu-Monette ZY, Wei L, Nunns H, Nagy ML, Bhagat G, Fang X, Zhu F, Visco C, Tzankov A, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Van Krieken JH, Piris MA, Winter JN, Li Y, Au Q, Xu B, Albitar M, Young KH. Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma. Oncoimmunology 10(1):1928365, 2021. e-Pub 2021. PMID: 34350060.
28. Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, Dai E, Dang M, Jain N, Yang H, Wang Y, Zhang S, Wang R, Chen R, Showell J, Ghosh S, Patchva S, Zhang Q, Sun R, Hagemeister F, Fayad L, Samaniego F, Lee HC, Nastoupil LJ, Fowler N, Eric Davis R, Westin J, Neelapu SS, Wang L, Green MR. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med 26(12):1878-1887, 2020. e-Pub 2020. PMID: 33020644.
29. Chin CK, Rodriguez MA, Qing Y, Feng L, Samaniego F, Jain P, Noorani M, Fowler NH, Fayad LE, Westin JR, Neelapu SS, Hagemeister FB, Flowers CR, Nastoupil LJ. Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma. Leuk Lymphoma 61(12):2985-2989, 2020. e-Pub 2020. PMID: 32628087.
30. Deng M, Zhang M, Xu-Monette ZY, Pham LV, Tzankov A, Visco C, Fang X, Bhagat G, Zhu F, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Choi WWL, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, van Krieken JH, Piris MA, Winter JN, Hagemeister F, Alinari L, Li Y, Andreeff M, Xu B, Young KH. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. J Hematol Oncol 13(1):148, 2020. e-Pub 2020. PMID: 33148342.
31. Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clin Cancer Res 26(21):5579-5587, 2020. e-Pub 2020. PMID: 33055173.
32. Strati P, Nastoupil LJ, Westin J, Fayad LE, Ahmed S, Fowler NH, Hagemeister FB, Lee HJ, Iyer SP, Nair R, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Adkins S, Claussen CM, Martinez CS, Hawkins MC, Johnson NA, Singh P, Mistry HE, Horowitz S, George S, Feng L, Kebriaei P, Shpall EJ, Neelapu SS, Tummala S, Chi TL. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv 4(16):3943-3951, 2020. e-Pub 2020. PMID: 32822484.
33. Xu-Monette ZY, Zhang H, Zhu F, Tzankov A, Bhagat G, Visco C, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, You H, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, van Krieken JH, Piris MA, Winter JN, Hagemeister FB, Shahbaba B, De Dios I, Zhang H, Li Y, Xu B, Albitar M, Young KH. A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. Blood Adv 4(14):3391-3404, 2020. e-Pub 2020. PMID: 32722783.
34. Strati P, Ahmed MA, Fowler NH, Nastoupil LJ, Samaniego F, Fayad LE, Hagemeister FB, Romaguera JE, Rodriguez A, Wang M, Westin JR, Cheah C, Noorani M, Feng L, Davis RE, Neelapu SS. Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. Haematologica 105(7):1907-1913, 2020. e-Pub 2020. PMID: 31601688.
35. Strati P, Ahmed MA, Nastoupil LJ, Feng L, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin JR, Lee HJ, Iyer SP, Parmar S, Ahmed S, Nair R, Steiner RE, Noorani M, Flowers CR, Davis RE, Fowler NH, Neelapu SS. Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. Leuk Lymphoma 61(6):1-8, 2020. e-Pub 2020. PMID: 31971032.
36. Zhou H, Xu-Monette ZY, Xiao L, Strati P, Hagemeister FB, He Y, Chen H, Li Y, Manyam GC, Li Y, Montes-Moreno S, Piris MA, Young KH. Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. Blood Cancer J 10(5):49, 2020. e-Pub 2020. PMID: 32366834.
37. Hu B, Nastoupil LJ, Loghavi S, Westin JR, Thakral B, Fayad LE, Hagemeister F, Neelapu S, Samaniego F, Lee HJ, Wang ML, Fanale M, Fowler N, Oki Y. De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. Leuk Lymphoma 61(2):1-9, 2020. e-Pub 2020. PMID: 31533521.
38. Strati P, Nastoupil LJ, Davis RE, Fayad LE, Fowler N, Hagemeister FB, Kwak L, Oki Y, Wang M, Westin J, Ruben CE, Wesson ET, Piekarz R, Fanale MA, Lee HJ. A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. Haematologica 105(1):e26-e28, 2020. e-Pub 2020. PMID: 31073068.
39. Sathyanarayanan V, Issa A, Pinto R, Fayad LE, Loghavi S, Hagemeister F, Westin JR. Rosai-Dorfman Disease: The MD Anderson Cancer Center Experience. Clin Lymphoma Myeloma Leuk 19(11):709-714, 2019. e-Pub 2019. PMID: 31446000.
40. Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM, Oran B, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemeister F, Champlin RE, Ciurea SO. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant 25(7):1340-1346, 2019. e-Pub 2019. PMID: 30763728.
41. Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, Hagemeister FB, Fanale MA, Fayad LE, Westin JR, Wang M, Oki Y, Forbes SG, Feng L, Neelapu SS, Fowler NH. Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol. e-Pub 2019. PMID: 30919940.
42. Khashab T, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Vega F, Kwak LW, Samaniego F. Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma. Br J Haematol. e-Pub 2019. PMID: 30820940.
43. Styskel BA, Lopez-Mattei J, Jimenez CA, Stewart J, Hagemeister FB, Faiz SA. Ibrutinib-Associated Serositis in Mantle Cell Lymphoma. Am J Respir Crit Care Med. e-Pub 2019. PMID: 30802411.
44. Strati P, Lee ST, Teegavarupu P, Karri A, Anireddy S, Hagemeister FB, Romaguera J, Fayad LE, Rodriguez MA, Samaniego F, Fowler N, Westin J, Wang M, Lee HJ, Pinnix C, Gunther JR, Dabaja B, Feng L, Davis RE, Neelapu SS. Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma. Am J Hematol. e-Pub 2019. PMID: 30785215.
45. Sheu T, Milgrom SA, Andraos TY, Gunther JR, Chi L, Nastoupil L, Fowler N, Oki Y, Fanale MA, Fayad LE, Hagemeister F, Neelapu SS, Medeiros LJ, Hosing C, Nieto Y, Ahmed S, Alousi AM, Dabaja B, Pinnix CC. Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. Adv Radiat Oncol 3(4):639-646, 2018. e-Pub 2018. PMID: 30370365.
46. Sagiv O, Thakar SD, Manning JT, Kandl TJ, Fayad LE, Fowler N, Hagemeister FB, Fanale MA, Pinnix CC, Samaniego F, Esmaeli B. Prevalence of a Histologic Change of Ocular Adnexal Lymphoma in Patients With a History of Lymphoma. Ophthalmic Plast Reconstr Surg. e-Pub 2018. PMID: 30124609.
47. Pinnix CC, Cella L, Andraos TY, Ayoub Z, Milgrom SA, Gunther J, Thosani S, Wogan C, Conson M, D'Avino V, Oki Y, Fanale M, Lee HJ, Neelapu S, Fayad L, Hagemeister F, Rodriguez MA, Nastoupil LJ, Nieto Y, Qiao W, Pacelli R, Dabaja B. Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy. Int J Radiat Oncol Biol Phys 101(3):530-540, 2018. e-Pub 2018. PMID: 29681481.
48. Romaguera JE, Wang M, Feng L, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Fanale M, Orlowski R, Kwak LW, Neelapu S, Oki Y, Pro B, Younes A, Samaniego F, Fowler N, Hartig K, Valentinetti M, Smith J, Ford P, Naig A, Medeiros LJ, Kantarjian HM, Goy A. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer 124(12):2561-2569, 2018. e-Pub 2018. PMID: 29723393.
49. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Ju Lee H, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck 40(6):1335, 2018. e-Pub 2018. PMID: 29851218.
50. Jain P, Romaguera J, Srour SA, Lee HJ, Hagemeister F, Westin J, Fayad L, Samaniego F, Badillo M, Zhang L, Nastoupil L, Kanagal-Shamanna R, Fowler N, Wang ML. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Br J Haematol. e-Pub 2018. PMID: 29785709.
51. Milgrom SA, Pinnix CC, Chi TL, Vu TH, Gunther JR, Sheu T, Fowler N, Westin JR, Nastoupil LJ, Oki Y, Fayad LE, Neelapu S, Rodriguez MA, Hagemeister FB, Fanale MA, Lee HJ, Hosing C, Ahmed S, Nieto Y, Shpall EJ, Dabaja BS. Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. Int J Radiat Oncol Biol Phys 100(5):1146-1154, 2018. e-Pub 2018. PMID: 29452771.
52. Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Copeland AR, Nastoupil LJ, Nieto Y, Fanale MA, Oki Y. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leuk Lymphoma 59(4):1-8, 2018. e-Pub 2018. PMID: 28792260.
53. Reddy JP, Hernandez M, Gunther JR, Dabaja BS, Martin GV, Jiang W, Akhtari M, Allen PK, Atkinson BJ, Smith GL, Pinnix CC, Milgrom SA, Abou Yehia Z, Osborne EM, Oki Y, Lee H, Hagemeister F, Fanale MA. Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma. Br J Haematol 180(4):545-549, 2018. e-Pub 2018. PMID: 29271057.
54. Strati P, Fowler N, Pina-Oviedo S, Medeiros LJ, Overman MJ, Romaguera JE, Nastoupil L, Wang M, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad L. Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. Clin Lymphoma Myeloma Leuk 18(1):e103-e108, 2018. e-Pub 2018. PMID: 29196178.
55. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Oki Y. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS One 13(3):e0191461, 2018. e-Pub 2018. PMID: 29538376.
56. Nair R, Tabchi S, Hagemeister F. Obinutuzumab Treatment of Follicular Lymphoma. N Engl J Med 377(26):2605, 2017. e-Pub 2017. PMID: 29281573.
57. Chihara D, Fowler NH, Oki Y, Fanale MA, Fayad LE, Westin JR, Hagemeister FB. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement. Br J Haematol 179(5):851-854, 2017. e-Pub 2017. PMID: 27502933.
58. Ho JC, Dabaja BS, Milgrom SA, Smith GL, Reddy JP, Mazloom A, Young KH, Deng L, Medeiros LJ, Dong W, Allen PK, Andraos TY, Fowler NH, Nastoupil LJ, Oki Y, Fayad LE, Turturro F, Neelapu SS, Westin J, Hagemeister FB, Rodriguez MA, Pinnix CC. Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma(). Leuk Lymphoma 58(12):1-12, 2017. e-Pub 2017. PMID: 28482717.
59. Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MA. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol 179(3):503-506, 2017. e-Pub 2017. PMID: 27378601.
60. Milgrom SA, Pinnix CC, Chuang H, Oki Y, Akhtari M, Mawlawi O, Garg N, Gunther JR, Reddy JP, Smith GL, Rohren E, Hagemeister FB, Lee HJ, Fayad LE, Dong W, Osborne EM, Abou Yehia Z, Fanale M, Dabaja BS. Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?. Br J Haematol 179(3):488-496, 2017. e-Pub 2017. PMID: 28832956.
61. Thuro BA, Ning J, Peng SA, Pace ST, Dudeja G, Ozgur O, Turturro F, Samaniego F, Hagemeister FB, Fayad LE, Fowler NH, Pinnix CC, Debnam JM, Esmaeli B. Rates of Positive Findings on Positron Emission Tomography and Bone Marrow Biopsy in Patients With Ocular Adnexal Lymphoma. Ophthal Plast Reconstr Surg 33(5):355-360, 2017. e-Pub 2017. PMID: 27636243.
62. Huang XJ, Liu K, Ritchie D, Andersson B, Lu J, Hou J, Burguera AF, Wang J, Yeoh A, Yan C, Zhou D, Tan D, Kim DW, Wu D, Shpall E, Kornblau S, Neelapu S, Hongeng S, Li J, Hu J, Zhang LS, Wang M, Malhotra P, Jiang Q, Qin Y, Wong R, Champlin R, Hagemeister F, Westin J, Iyer S, Mathews V, Wang Y, Hu Y, Xiao Z, Shao Z, Orlowski RZ, Chim CS, Mulligan S, Sanz M, Ozawa K, Parmar S, Issaragrisil S. Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. Oncotarget 8(25):41620-41630, 2017. e-Pub 2017. PMID: 28404929.
63. Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad L, Hagemeister FB, Samaniego F, Rodriguez MA, Neelapu SS, Lee HJ, Nastoupil L, Fowler N, Turturro F, Westin J, Wang M, McLaughlin P, Pinnix C, Milgrom S, Dabaja B, Horowitz SB, Younes A. Encouraging activity for R-CHOP in Advanced Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma. Blood. e-Pub 2017. PMID: 28522441.
64. Lee HJ, Romaguera JE, Feng L, Desai AP, Zhang L, Fanale M, Samaniego F, Hagemeister FB, Fayad LE, Rodriguez MA, Medeiros JL, Hartig K, Nomie K, Ahmed M, Badillo M, Ye H, Oki Y, Lin P, Nastoupil L, Westin J, Wang M. Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. Oncologist 22(5):549-553, 2017. e-Pub 2017. PMID: 28408615.
65. Nastoupil LJ, McLaughlin P, Feng L, Neelapu SS, Samaniego F, Hagemeister FB, Ayala A, Romaguera JE, Goy AH, Neal E, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Fowler NH. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. Br J Haematol 177(2):263-270, 2017. e-Pub 2017. PMID: 28340281.
66. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. e-Pub 2017. PMID: 28370694.
67. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki Y. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. e-Pub 2016. PMID: 27983760.
68. Xu-Monette ZY, Li L, Byrd JC, Jabbar KJ, Manyam GC, de Winde CM, van den Brand M, Tzankov A, Visco C, Wang J, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Wang M, Hagemeister FB, Piris MA, van Krieken JH, Medeiros LJ, Li Y, van Spriel AB, Young KH. Assessment of CD37 B-cell antigen and cell-of-origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood. e-Pub 2016. PMID: 27760757.
69. Pinnix CC, Osborne EM, Chihara D, Lai P, Zhou S, Ramirez MM, Oki Y, Hagemeister FB, Rodriguez AM, Samaniego F, Fowler N, Romaguera JE, Turturro F, Fayad L, Westin JR, Nastoupil L, Neelapu SS, Cheah CY, Dabaja BS, Milgrom SA, Smith GL, Horace P, Milbourne A, Wogan CF, Ballas L, Fanale MA. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. JAMA Oncol 2(8):1065-9, 2016. e-Pub 2016. PMID: 27227654.
70. Chen Y, Neelapu S, Feng L, Bi W, Yang TH, Wang M, Fanale MA, Westin JR, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Fowler NH, McLaughlin P, Cabanillas F, Oki Y, Nastoupil LJ, Rodriguez A. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br J Haematol. e-Pub 2016. PMID: 27448187.
71. Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F, Anderlini P, Nieto Y, Fanale MA. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol 27(7):1317-23, 2016. e-Pub 2016. PMID: 27091808.
72. Anderlini P, Saliba RM, Ledesma C, Plair T, Alousi AM, Hosing CM, Khouri IF, Nieto Y, Popat UR, Shpall EJ, Fanale MA, Hagemeister FB, Oki Y, Neelapu S, Romaguera JE, Younes A, Champlin RE. Gemcitabine, fludarabine and melphalan for reduced-intensity conditioning and allogeneic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 22(7):1333-7, 2016. e-Pub 2016. PMID: 27064056.
73. Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer. e-Pub 2016. PMID: 27351173.
74. Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, Fowler NH. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol 27(5):895-901, 2016. e-Pub 2016. PMID: 26802151.
75. Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clin Lymphoma Myeloma Leuk 16(3):122-8, 2016. e-Pub 2016. PMID: 26795083.
76. Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak LW, Wang ML, Romaguera JE. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol 172(1):80-8, 2016. e-Pub 2016. PMID: 26648336.
77. Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Oki Y, Chen W, Badillo M, Nomie K, DeLa Rosa M, Zhao D, Lam L, Addison A, Zhang H, Young KH, Li S, Santos D, Medeiros LJ, Champlin R, Romaguera J, Zhang L. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol 17(1):48-56, 2016. e-Pub 2016. PMID: 26640039.
78. Sathyanarayanan V, Hagemeister F. Targeted therapies for Hodgkin lymphoma: results of recent trials. Rinsho Ketsueki 57(10):2049-2053, 2016. e-Pub 2016. PMID: 27795513.
79. Cheah CY, Nastoupil LJ, McLaughlin P, Fanale MA, Neelapu SS, Fayad LE, Hagemeister FB, Fowler NH. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity. Br J Haematol. e-Pub 2015. PMID: 26683805.
80. Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JA. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol 171(5):726-35, 2015. e-Pub 2015. PMID: 26358140.
81. Fowler NH, Nastoupil LJ, Hagemeister FB, Neelapu SS, Fayad LE, LeBlanc D, Samaniego F, Cheah CY. Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma. Haematologica 100(11):e454-7, 2015. e-Pub 2015. PMID: 26250576.
82. Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N, Bashir Q, Liu Y, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant 21(11):1914-20, 2015. e-Pub 2015. PMID: 26071868.
83. Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol 171(4):509-16, 2015. e-Pub 2015. PMID: 26260306.
84. Oki Y, Younes A, Knickerbocker J, Samaniego F, Nastoupil L, Hagemeister F, Romaguera J, Fowler N, Kwak L, Westin J. Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica 100(7):e272-4, 2015. e-Pub 2015. PMID: 25820332.
85. Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, Champlin RE, Wang ML. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol 26(6):1175-9, 2015. e-Pub 2015. PMID: 25712454.
86. Samaniego F, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Berkova Z, Khashab T, Sehgal L, Vega-Vasquez F, Kwak LW. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. Br J Haematol 169(6):814-23, 2015. e-Pub 2015. PMID: 25828695.
87. Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by (18)fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys 92(1):113-21, 2015. e-Pub 2015. PMID: 25863759.
88. Pinnix CC, Smith GL, Milgrom S, Osborne EM, Reddy JP, Akhtari M, Reed V, Arzu I, Allen PK, Wogan CF, Fanale MA, Oki Y, Turturro F, Romaguera J, Fayad L, Fowler N, Westin J, Nastoupil L, Hagemeister FB, Rodriguez MA, Ahmed S, Nieto Y, Dabaja B. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for hodgkin and non-hodgkin lymphoma. Int J Radiat Oncol Biol Phys 92(1):175-82, 2015. e-Pub 2015. PMID: 25863764.
89. Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA. Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial. Clin Lymphoma Myeloma Leuk 15(3):152-8, 2015. e-Pub 2015. PMID: 25445468.
90. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 15(12):1311-8, 2014. e-Pub 2014. PMID: 25439689.
91. Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 167(2):177-84, 2014. e-Pub 2014. PMID: 25039868.
92. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double Hit Lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 166(6):891-901, 2014. e-Pub 2014. PMID: 24943107.
93. Dabaja BS, Hess K, Shihadeh F, Podoloff DA, Medeiros LJ, Mawlawi O, Arzu I, Oki Y, Hagemeister FB, Fayad LE, Reed VK, Kedir A, Wogan CF, Rodriguez A. Positron Emission Tomography/Computed Tomography Findings During Therapy Predict Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy Alone but Not in Those Who Receive Consolidation Radiation. Int J Radiat Oncol Biol Phys 89(2):384-91, 2014. e-Pub 2014. PMID: 24721592.
94. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 165(1):112-6, 2014. e-Pub 2014. PMID: 24386943.
95. Thompson MA, Westin JR, Hagemeister FB. Bone mineral density screening should be routine in lymphoma patients. Ann Oncol 25(4):913-4, 2014. e-Pub 2014. PMID: 24667725.
96. Dabaja BS, Phan J, Mawlawi O, Medeiros LJ, Etzel C, Liang FW, Podoloff D, Oki Y, Hagemeister FB, Chuang H, Fayad LE, Westin JR, Shihadeh F, Allen PK, Wogan CF, Rodriguez MA. Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. Leuk Lymphoma 54(12):2631-8, 2013. e-Pub 2013. PMID: 23488661.
97. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol 163(5):611-20, 2013. e-Pub 2013. PMID: 24117234.
98. Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Romaguera J, Kwak LW, Pro B, de Castro Faria S, Neelapu S, Fowler N, Hagemeister F, Zhang J, Zhou S, Feng L, Younes A. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res 19(24):6882-90, 2013. e-Pub 2013. PMID: 24097867.
99. Westin J, Hagemeister F. R-CHOP every 21 days for diffuse large B-cell lymphoma: still the standard of care?. J Comp Eff Res 2(6):537-40, 2013. e-Pub 2013. PMID: 24236792.
100. Hagemeister F, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A, Dang NH, Forman A, McLaughlin P, Medeiros LJ, Pro B, Romaguera J, Samaniego F, Silverman JA, Sarris A, Cabanillas F. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. Br J Haematol 162(5):631-8, 2013. e-Pub 2013. PMID: 23802738.
101. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 27(9):1902-9, 2013. e-Pub 2013. PMID: 23545991.
102. Oki Y, Younes A, Copeland A, Hagemeister F, Fayad LE, McLaughlin P, Shah J, Fowler N, Romaguera J, Kwak LW, Pro B. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol 162(1):138-41, 2013. e-Pub 2013. PMID: 23590726.
103. Churpek JE, Pro B, van Besien K, Kline J, Conner K, Wade JL, Hagemeister F, Karrison T, Smith SM. A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas. Cancer 119(9):1683-9, 2013. e-Pub 2013. PMID: 23310949.
104. Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemeister FB. Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial. Clin Lymphoma Myeloma Leuk 13(2):99-105, 2013. e-Pub 2013. PMID: 23276888.
105. Batty N, Ghonimi E, Feng L, Fayad L, Younes A, Rodriguez MA, Romaguera JE, McLaughlin P, Samaniego F, Kwak LW, Hagemeister FB. The Absolute Monocyte and Lymphocyte Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma Who Receive R-CHOP. Clin Lymphoma Myeloma Leuk 13(1):15-8, 2013. e-Pub 2013. PMID: 23137719.
106. Hagemeister FB. 'Watch and wait' as initial management for patients with follicular lymphomas: still a viable strategy?. BioDrugs 26(6):363-76, 2012. e-Pub 2012. PMID: 23057946.
107. Younes A, Romaguera J, Fanale M, McLaughlin P, Hagemeister F, Copeland A, Neelapu S, Kwak L, Shah J, de Castro Faria S, Hart S, Wood J, Jayaraman R, Ethirajulu K, Zhu J. Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes. J Clin Oncol 30(33):4161-7, 2012. e-Pub 2012. PMID: 22965964.
108. Younes A, Kim S, Romaguera J, Copeland A, Farial Sde C, Kwak LW, Fayad L, Hagemeister F, Fanale M, Neelapu S, Lambert JM, Morariu-Zamfir R, Payrard S, Gordon LI. Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma. J Clin Oncol 30(22):2776-82, 2012. e-Pub 2012. PMID: 22753910.
109. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 13(7):716-23, 2012. e-Pub 2012. PMID: 22677155.
110. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol 23(6):1640-5, 2012. e-Pub 2012. PMID: 22015451.
111. Batty N, Hagemeister FB, Feng L, Romaguera JE, Rodriguez MA, McLaughlin P, Samaniego F, Copeland A, Dabaja BS, Younes A. Doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin's lymphoma: A 10-year follow-up study. Leuk Lymphoma 53(5):801-6, 2012. e-Pub 2012. PMID: 22023528.
112. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 119(18):4123-8, 2012. e-Pub 2012. PMID: 22371887.
113. Oki Y, Copeland A, Hagemeister F, Fayad LE, Fanale M, Romaguera J, Younes A. Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood 119(9):2171-2, 2012. e-Pub 2012. PMID: 22383790.
114. Shah N, Cabanillas F, McIntyre B, Feng L, McLaughlin P, Rodriguez MA, Romaguera J, Younes A, Hagemeister FB, Kwak L, Fayad L. Prognostic value of serum CD44, ICAM-1 and VCAM-1 levels in patients with indolent non-Hodgkin lymphomas. Leuk Lymphoma 53(1):50-6, 2012. e-Pub 2012. PMID: 21895545.
115. Thomas DA, O'Brien S, Faderl S, Jr MJ, Romaguera JE, Fayad L, Hagemeister F, Medeiros J, Cortes J, Kantarjian H. Burkitt lymphoma and atypical Burkitt-like lymphoma: Should these be treated as different diseases?. Curr Hematol Malig Rep 6(1):58-66, 2011. e-Pub 2011. PMID: 21191675.
116. Zhou X, Teegala S, Huen A, Ji Y, Fayad L, Hagemeister FB, Gladish G, Vadhan-Raj S. Incidence and risk factors of venous thromboembolic events in lymphoma. Am J Med 123(10):935-941, 2010. e-Pub 2010. PMID: 20920696.
117. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L, Wang M. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150(2):200-208, 2010. e-Pub 2010.
118. Morris GJ, Dotan E, Smith MR, Jr HF, Brereton HD. Gastric mucosa-associated lymphoid tissue lymphoma. Semin Oncol 37(3):183-7, 2010. e-Pub 2010. PMID: 20709202.
119. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Copeland A, Samuels BI, Loyer EM, Ji Y, Younes A. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 27(31):5213-8, 2009. e-Pub 2009. PMID: 19770379.
120. Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C, Kebraei P, Harrell R, Rondon G, Giralt SA, Anderlini P, Popat U, Pro B, Samuels B, Hagemeister F, Medeiros LJ, Champlin RE, Khouri IF. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113(18):4144-52, 2009. e-Pub 2009. PMID: 19168784.
121. Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, Romaguera J, Cabanillas F, Neelapu SS, Banay R, Rayad L, Wayne SM, Kwak LW. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Annals of Oncology 20(4):709-14, 2009. e-Pub 2009. PMID: 19150940.
122. Morschauser F, Dreyling M, Rohatiner A, Hagemeister F, Bischof-Delaloye A. Rationale for consolidation to improve progression-free survival in patinets with non-Hodgkin's lymphoma: a review of the evidence. The Oncologist 14(Suppl 2):17-29, 2009. e-Pub 2009. PMID: 19819921.
123. Overman, MJ, Feng, L, Pro, B, McLaughlin, P, Hess, M, Samaniego, F, Younes, A, Romaguera, JE, Hagemeister, FB, Kwak, L, Cabanillas, F, Rodriguez, MA, Fayad, LE. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Ann Oncol 19 (3)(3):553-559, 2008. e-Pub 2008. PMID: 18083690.
124. Oki, Y, Pro, B, Fayad, LE, Romaguera, J, Samaniego, F, Hagemeister, F, Neelapu, S, McLaughlin, P, Goy, A, Younes, A. Phase 2 study of gemcitabine in combination with Rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 112 (4):831-836, 2008. e-Pub 2008.
125. Anderlini P, Saliba R, Acholonu S, Giralt SA, Anderson B, Ueno NT, Hosing C, Khouri IF, Couriel D, de Lima M, Qazilbash MH, Pro B, Romaguera J, Fayad L, Hagemeister F, Younes A, Munsell MF, Champlin RE. Fludarabine-Melphalan as preparative regimen for reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's Lymphoma: The updated M.D. Anderson Cancer Center experience. Hematological 93 (2):257-64, 2008. e-Pub 2008.
126. Leonard JP, Friedberg JW, Hagemeister FB, Levine AM. Combination treatment of approaches and novel therapies for lymphoma. Clinical Advances of Hematology Oncology 8(12):4-20, 2007. e-Pub 2007.
127. Hagemeister FB, Fayad L. The FLIPI and the R-FLIPI: Are we finally ready to use them in clinical trials?. Am J Hematol/Onc 6:364-68, 2007. e-Pub 2007.
128. Dang NH, Pro B, Hagemeister FB, Samaniego F, Jones D, Samuels BI, Rodriguez MA, Goy A, Romaguera JE, McLaughlin P, Tong AT, Turturro F, Walker PL, Fayad L. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 136(3):439-47, 2007. e-Pub 2007. PMID: 17233846.
129. Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B, Khouri I, Younes A, Hagemeister FB, Kwak L, Fayad L. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 109(12):2481-89, 2007. e-Pub 2007.
130. Fayad L, Hagemeister FB. Treatment of the patient with diffuse large B-cell lymphoma with medical co-morbidities: Newer therapies needed. Leuk Lymphoma 48:657-58, 2007. e-Pub 2007.
131. Hagemeister FB. Hodgkin's Lymphoma in the Elderly: Who is "Older" and is the Disease Really Worse in Older Patients?. Oncology 21:996-1002, 2007. e-Pub 2007.
132. Hagemeister FB. Hodgkin’s lymphoma in younger patients: Lessons learned on the road to success. Oncology (Williston Park) 21:434-40, 2007. e-Pub 2007.
133. Dang NH, Fayad L, McLaughlin P, Romaguera JE, Hagemeister FB, Goy A, Neelapu S, Samaniego F, Walker PL, Wang M, Rodriguez MA, Tong AT, Pro B. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin’s lymphoma. Br J Haematol 138(4):502-05, 2007. e-Pub 2007.
134. Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, Romaguera JE, Goy AH, Hagemeister FB, McLaughlin P, Bodey GP, Kwak LW, Raad, II, Couch RB. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis 194(10):1394-7, 2006. e-Pub 2006. PMID: 17054068.
135. Samaniego, F, Fayad, LE, Pro, B, McLaughlin, P, Rodriguez, MA, Hagemeister, FB, Fanale, M, Neelapu, S, Younes, A, Kwak, LW. Pentostatin combined with cyclophosphamide, and rituximab induces high response rates in patients with untreated indolent B-cell lymphoma. Blood 108(11):263B-263B, 2006. e-Pub 2006.
136. Pro B, Hagemeister FB, McLaughlin P, Romaguera J, Rodriguez MA, Cabanillas F, Tiongson LP, Younes A. Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma. Leuk Lymphoma 47(9):1818-21, 2006. e-Pub 2006. PMID: 17064994.
137. Tsimberidou AM, O'Brien S, Kantarjian HM, Koller C, Hagemeister FB, Fayad L, Lerner S, Bueso-Ramos CE, Keating MJ. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer 107(6):1294-302, 2006. e-Pub 2006. PMID: 16902984.
138. Pro B, Fayad L, McLaughlin P, Romaguera J, Hagemeister FB, Rodriguez MA, Goy A, Loyer E, Younes A. Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 47(3):481-85, 2006. e-Pub 2006. PMID: 16396772.
139. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H. Chemoimmunotherapy with hyper-CVAD plus Rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106(7):1569-80, 2006. e-Pub 2006. PMID: 16502413.
140. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, Romaguera JE, Rodriguez MA, Tsimberidou AM, Verstovsek S, Younes A, Pro B, Lee MS, Ayala A, McLaughlin P. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol 24(10):1582-89, 2006. e-Pub 2006. PMID: 16575009.
141. Oki Y, McLaughlin P, Pro B, Hagemeister FB, Bleyer A, Loyer E, Younes A. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma. Cancer 104(4):781-7, 2005. e-Pub 2005. PMID: 15973667.
142. Tsimberidou AM, Younes A, Romaguera J, Hagemeister FB, Rodriguez MA, Feng L, Ayala A, Smith TL, Cabanillas F, McLaughlin P. Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. Cancer 104(2):345-53, 2005. e-Pub 2005. PMID: 15948158.
143. McLaughlin P, Estey E, Glassman A, Romaguera J, Samaniego F, Ayala A, Hayes K, Maddox AM, Preti HA, Hagemeister FB. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood 105(12):4573-5, 2005. e-Pub 2005. PMID: 15741224.
144. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23:667-75, 2005. e-Pub 2005. PMID: 15613697.
145. Poonwalla T, Jones D, Hagemeister FB, Duvic H. Acral necrotizing mycosis fungoides. Clin Lymph Myel 6:146-48, 2005. e-Pub 2005.
146. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF. High rate of durable remissions after treatment of newly diagnosed aggressive mantle cell lymphoma with Rituximab plus hyper-CVAD alternating with Rituximab plus high-dose Methotrexate and Cytarabine. J Clin Oncol 23(28):7013-23, 2005. e-Pub 2005. PMID: 16145068.
147. Hagemeister FB. Stem-cell transplant for Hodgkin's lymphoma: Does choice of therapy prior to high-dose treatment matter?. Nat Clin Pract Oncol 2(7):344-45, 2005. e-Pub 2005. PMID: 16075792.
148. Oky Y, McLaughlin P, Pro B, Hagemeister FB, Bleyer A, Loyer E, Younes A. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin's lymphoma. Cancer 104:781-87, 2005. e-Pub 2005.
149. Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 22(20):4095-102, 2004. e-Pub 2004. PMID: 15353540.
150. Younes A, Pro B, Robertson MJ, Flinn IW, Romaguera JE, Hagemeister F, Dang NH, Fiumara P, Loyer EM, Cabanillas FF, McLaughlin PW, Rodriguez MA, Samaniego F. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin Cancer Res 10:5432-8, 2004. e-Pub 2004. PMID: 15328181.
151. Khoury JD, Jones D, Yared MA, Manning JT, Jr, Abruzzo LV, Hagemeister FB, Medeiros LJ. Bone marrow involvement in patients with nodular lymphocyte predominant Hodgkin lymphoma. Am J Surg Pathol 28(4):489-95, 2004. e-Pub 2004. PMID: 15087668.
152. Pro B, Younes A, Albitar M, Dang NH, Samaniego F, Romaguera J, McLaughlin P, Hagemeister FB, Rodriguez MA, Clemons M, Cabanillas F. Thalidomide for patients with recurrent lymphoma. Cancer 100(6):1186-9, 2004. e-Pub 2004. PMID: 15022285.
153. Chronowski GM, Wilder RB, Levy LB, Atkinson EN, Ha CS, Hagemeister FB, Barista I, Rodriguez MA, Sarris AH, Hess MA, Cabanillas F, Cox JD. Second malignancies after chemotherapy and radiotherapy for Hodgkin disease. Am J Clin Oncol 27(1):73-80, 2004. e-Pub 2004. PMID: 14758137.
154. Hagemeister F. Does high-dose therapy cure more patients with large cell lymphoma than standard CHOP? . Am J Onc Rev 3:68-72, 2004. e-Pub 2004.
155. Chronowski GM, Wilder RB, Levy LB, Atkinson EN, Ha CS, Hagemeister FB, Barista I, Rodriguez MA, Sarris AH, Hess MA, Cabanillas F, Cox JD. Second malignancies after chemotherapy and radiotherapy for Hodgkin's disease. Am J Clin Oncol 27:73-80, 2004. e-Pub 2004.
156. Dang NH, Hagemeister FB, Duvic M, Romaguera JE, Younes A, Jones D, Samuels B, Fayad LE, Pro B, Samaniego F, Sarris A, Goy A, McLaughlin P, Tong AT, Walker PL, Tiongson LP, Smith TL, Huh YO, Morimoto C, Rodriguez MA. Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. Oncol Rep 10(5):1513-8, 2003. e-Pub 2003. PMID: 12883733.
157. Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, Goy A, Jeha S, Manning JT, Jr, Jones D, Abruzzo LV, Medeiros LJ. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 98:310-4, 2003. e-Pub 2003. PMID: 12872350.
158. Romaguera JE, Medeiros LJ, Hagemeister FB, Fayad LE, Rodriguez MA, Pro B, Younes A, McLaughlin P, Goy A, Sarris AH, Dang NH, Samaniego F, Brown HM, Gagneja HK, Cabanillas F. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 97(3):586-91, 2003. e-Pub 2003. PMID: 12548600.
159. Chronowski GM, Wilder RB, Tucker SL, Ha CS, Younes A, Fayad L, Rodriguez MA, Hagemeister FB, Barista I, Cabanillas F, Cox JD. Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. Int J Radiat Oncol Biol Phys 55(1):36-43, 2003. e-Pub 2003. PMID: 12504034.
160. Hagemeister F. Should we continue trials of BMT as initial therapy for aggressive lymphomas at high risk of relapse? . Am J Onc Rev 8:416-417, 2003. e-Pub 2003.
161. Frias S, Van Hummelen P, Meistrich ML, Lowe XR, Hagemeister FB, Shelby MD, Bishop JB, Wyrobek AJ. NOVP chemotherapy for Hodgkin's disease transiently induces sperm aneuploidies associated with the major clinical aneuploidy syndromes involving chromosomes X, Y, 18, and 21. Cancer Res 63(1):44-51, 2003. e-Pub 2003. PMID: 12517776.
162. Chronowski GM, Wilder RB, Tucker SL, Ha CS, Sarris AH, Hagemeister FB, Barista I, Hess MA, Cabanillas F, Cox JD. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. Cancer 95(12):2534-8, 2002. e-Pub 2002. PMID: 12467067.
163. Tsimberidou AM, McLaughlin P, Younes A, Rodriguez MA, Hagemeister FB, Sarris A, Romaguera J, Hess M, Smith TL, Yang Y, Ayala A, Preti A, Lee MS, Cabanillas F. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood 100(13):4351-7, 2002. e-Pub 2002. PMID: 12393618.
164. Schlembach PJ, Wilder RB, Jones D, Ha CS, Fayad LE, Younes A, Hagemeister F, Hess M, Cabanillas F, Cox JD. Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. Cancer J 8:377-83, 2002. e-Pub 2002. PMID: 12416895.
165. Sarris AH, Phan A, Goy A, Romaguera J, Hagemeister FB, Rodriguez MA, McLaughlin P, Pro B, Medeiros LJ, Samuels B, Mesina O, Bleyer AW, Cabanillas F. Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial. Oncology (Williston Park) 16(8 Suppl 7):27-31, 2002. e-Pub 2002. PMID: 12199630.
166. Wilder RB, Schlembach PJ, Jones D, Chronowski GM, Ha CS, Younes A, Hagemeister FB, Barista I, Cabanillas F, Cox JD. European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer 94(6):1731-8, 2002. e-Pub 2002. PMID: 11920535.
167. Barista I, Cabanillas F, Romaguera JE, Khouri IF, Yang Y, Smith TL, Strom SS, Medeiros LJ, Hagemeister FB. Is there an increased rate of additional malignancies in patients with mantle cell lymphoma?. Ann Oncol 13(2):318-22, 2002. e-Pub 2002. PMID: 11886011.
168. Hagemeister FB. Rituximab plus hyper-CVAD for mantle cell lymphoma: Updated results. Biol Ther of Lymph 5:3-6, 2002. e-Pub 2002.
169. Barista I, Cabanillas F, Romaguera JE, Khouri IF, Yang Y, Smith TL, Strom SS, Medeiros LJ, Hagemeister FB. Is there an increased rate of additional malignancies in patients with mantle cell lymphoma?. Annals of Oncology 13:318-22, 2002. e-Pub 2002.
170. Hagemeister, Fredrick. Treatment Options for Aggressive Lymphomas. Lymph Biol & Res 7:8, 2002. e-Pub 2002.
171. Hagemeister FB. Review of a randomized controlled trial of Yttruim-90-labeled Ibritumomab Tiuxetan radioimmunotherapy versus Rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Am J Oncol Rev 1:222-24, 2002. e-Pub 2002.
172. Chronowski GM, Wilder RB, Tucker SL, Ha CS, Sarris AH, Hagemeister FB, Barista I, Hess MA, Cabanillas F, Cox JD. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. Cancer 95:2534-8, 2002. e-Pub 2002.
173. Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB, Korbling M, Younes A, Ippoliti C, Gajewski JL, McLaughlin P, Anderlini P, Donato ML, Cabanillas FF, Champlin RE. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98(13):3595-9, 2001. e-Pub 2001. PMID: 11739162.
174. Rodriguez J, Munsell M, Yazji S, Hagemeister FB, Younes A, Andersson B, Giralt S, Gajewski J, de Lima M, Couriel D, Romaguera J, Cabanillas FF, Champlin RE, Khouri IF. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 19(17):3766-70, 2001. e-Pub 2001. PMID: 11533100.
175. Sarris AH, Romaguera J, Hagemeister FB, Rodriguez MA, McLaughlin P, Pro B, Younes A, Mesina O, Cabanillas F, Medeiros LJ, Samuels B. Irinotecan in relapsed or refractory non-Hodgkin's lymphoma. Oncology (Williston Park) 15(7 Suppl 8):53-6, 2001. e-Pub 2001. PMID: 11497233.
176. Younes A, Preti HA, Hagemeister FB, McLaughlin P, Romaguera JE, Rodriguez MA, Samuels BI, Palmer JL, Cabanillas F. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 12(7):923-7, 2001. e-Pub 2001. PMID: 11521796.
177. Liao Z, Ha CS, Vlachaki MT, Hagemeister F, Cabanillas F, Hess M, Tucker S, Cox JD. Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure. Int J Radiat Oncol Biol Phys 50:971-7, 2001. e-Pub 2001. PMID: 11429225.
178. Visco C, Medeiros LJ, Mesina OM, Rodriguez MA, Hagemeister FB, McLaughlin P, Romaguera JE, Cabanillas F, Sarris AH. Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy?. Clin Lymphoma 2(1):40-6, 2001. e-Pub 2001. PMID: 11707869.
179. Tsimberidou AM, Sarris AH, Medeiros LJ, Mesina O, Rodriguez MA, Hagemeister FB, Romaguera J, Pro B, McLaughlin P, Dang N, Cabanillas F. Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcome. Leuk Lymphoma 41(5-6):535-44, 2001. e-Pub 2001. PMID: 11378571.
180. Sarris AH, Braunschweig I, Medeiros LJ, Duvic M, Ha CS, Rodriguez MA, Hagemeister FB, McLaughlin P, Romaguera J, Cox J, Cabanillas F. Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapy. J Clin Oncol 19(2):398-405, 2001. e-Pub 2001. PMID: 11208831.
181. Younes A, Cristofanilli M, McLaughlin P, Hagemeister FB, Weber D, Mesina O, Cabanillas F. Experience with 9-cis retinoic acid in patients with relapsed and refractory non-Hodgkin's lymphoma. Leuk Lymphoma 40(1-2):79-85, 2000. e-Pub 2000. PMID: 11426631.
182. McLaughlin P, Hagemeister FB, Rodriguez MA, Sarris AH, Pate O, Younes A, Lee MS, Dang NH, Romaguera JE, Preti AH, McAda N, Cabanillas F. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 27(6 Suppl 12):37-41, 2000. e-Pub 2000. PMID: 11225999.
183. Rodriguez J, McLaughlin P, Fayad L, Santiago M, Hess M, Rodriguez MA, Romaguera J, Hagemeister F, Kantarjian H, Cabanillas F. Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981. Ann Oncol 11(12):1551-6, 2000. e-Pub 2000. PMID: 11205462.
184. Sarris AH, Psyrri A, Hagemeister F, Romaguera J, McLaughlin P, Rodriguez MA, Bachier C, Younes A, Mesina O, Oholendt M, Medeiros LJ, Samuels B, Adams LM, Cabanillas F. Infusional vinorelbine in relapsed or refractory lymphomas. Leuk Lymphoma 39(3-4):291-9, 2000. e-Pub 2000. PMID: 11342309.
185. Anderlini P, Giralt S, Andersson B, Ueno NT, Khouri I, Acholonu S, Cohen A, Korbling MJ, Manning J, Romaguera J, Sarris A, Rodriguez, Hagemeister F, McLaughlin P, Cabanillas F, Champlin RE. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant 26(6):615-20, 2000. e-Pub 2000. PMID: 11041566.
186. Romaguera JE, Khouri IF, Kantarjian HM, Hagemeister FB, Rodriguez MA, McLaughlin P, Sarris AH, Younes A, Rodriguez J, Cabanillas F. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma 39(1-2):77-85, 2000. e-Pub 2000. PMID: 10975386.
187. Lopez-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Rodriguez MA, Romaguera JE, Younes A, Sarris AH, Preti HA, Pugh W, Lee MS. Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series. Ann Oncol 11 Suppl 1:137-40, 2000. e-Pub 2000. PMID: 10707796.
188. Zheng N, Monckton DG, Wilson G, Hagemeister F, Chakraborty R, Connor TH, Siciliano MJ, Meistrich ML. Frequency of minisatellite repeat number changes at the MS205 locus in human sperm before and after cancer chemotherapy. Environ Mol Mutagen 36(2):134-45, 2000. e-Pub 2000. PMID: 11013412.
189. Dubey P, Wilson G, Mathur KK, Hagemeister FB, Fuller LM, Ha CS, Cox JD, Meistrich ML. Recovery of sperm production following radiation therapy for Hodgkin's disease after induction chemotherapy with mitoxantrone, vincristine, vinblastine, and prednisone (NOVP). Int J Radiat Oncol Biol Phys 46(3):609-17, 2000. e-Pub 2000. PMID: 10701740.
190. Sarris AH, Hagemeister F, Romaguera J, Rodriguez MA, McLaughlin P, Tsimberidou AM, Medeiros LJ, Samuels B, Pate O, Oholendt M, Kantarjian H, Burge C, Cabanillas F. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol 11(1):69-72, 2000. e-Pub 2000. PMID: 10690390.
191. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 26(5 Suppl 14):79-87, 1999. e-Pub 1999. PMID: 10561022.
192. Donato ML, Champlin RE, Van Besien KW, Korbling M, Cabanillas F, Anderlini P, Gajewski JG, Lauppe J, Durett A, Andersson B, Giralt S, Khouri I, Hagemeister F, Romaguera JE, Sarris A, McLaughlin P, Younes A, Ippoliti C, Blamble DA, Hester J, Gee A, Rodriguez MA. Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 35(3-4):317-24, 1999. e-Pub 1999. PMID: 10706456.
193. Khouri, I, Romaguera J, Kantarjian H, Korbling M, Younes A, Giralt S, Hagemeister F, Gajewski J, Sarris A, Claxton D, McLaughlin P, Donato M, Rodriguez M, Ueno N, Champlin R, Cabanillas F. Update of the HCVAD regimen followed by stem cell transplantation (SCT) in mantle cell lymphoma (MCL). . Blood 94(suppl 1):610a, 1999. e-Pub 1999.
194. Thomas DA, Cortes J, O'Brien S, Pierce S, Faderl S, Albitar M, Hagemeister FB, Cabanillas FF, Murphy S, Keating MJ, Kantarjian H. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 17(8):2461-70, 1999. e-Pub 1999. PMID: 10561310.
195. Steinbach G, Ford R, Glober G, Sample D, Hagemeister FB, Lynch PM, McLaughlin PW, Rodriguez MA, Romaguera JE, Sarris AH, Younes A, Luthra R, Manning JT, Johnson CM, Lahoti S, Shen Y, Lee JE, Winn RJ, Genta RM, Graham DY, Cabanillas FF. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med 131(2):88-95, 1999. e-Pub 1999. PMID: 10419446.
196. Rodriguez, J, Khouri I, Palmer L, Rodriguez M, Hagemeister F, Korbling M, Younes A, McLaughlin P, Cabanillas F, Chaplin R. Salvage therapy with hematopoietic cell transplantation (HCT) in peripheral T-cell lymphomas (PTCL). . Blood 94:172a, 1999. e-Pub 1999.
197. Rodriguez J, Rodriguez MA, Fayad L, McLaughlin P, Swan F, Sarris A, Romaguera J, Andersson B, Cabanillas F, Hagemeister FB. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood 93(11):3632-6, 1999. e-Pub 1999. PMID: 10339468.
198. Lopez-Guillermo A, Cabanillas F, McDonnell TI, McLaughlin P, Smith T, Pugh W, Hagemeister F, Rodriguez MA, Romaguera JE, Younes A, Sarris AH, Preti HA, Lee MS. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood 93(9):3081-7, 1999. e-Pub 1999. PMID: 10216105.
199. Przepiorka D, van Besien K, Khouri I, Hagemeister F, Samuels B, Folloder J, Ueno NT, Molldrem J, Mehra R, Korbling M, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, Andersson B, Anderlini P, Champlin R. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol 10(5):527-32, 1999. e-Pub 1999. PMID: 10416001.
200. Rodriguez J, McLaughlin P, Hagemeister FB, Fayad L, Rodriguez MA, Santiago M, Hess M, Romaguera J, Cabanillas F. Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. Blood 93(7):2202-7, 1999. e-Pub 1999. PMID: 10090928.
201. Sarris AH, Kliche KO, Pethambaram P, Preti A, Tucker S, Jackow C, Messina O, Pugh W, Hagemeister FB, McLaughlin P, Rodriguez MA, Romaguera J, Fritsche H, Witzig T, Duvic M, Andreeff M, Cabanillas F. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol 10(4):433-40, 1999. e-Pub 1999. PMID: 10370786.
202. Ha CS, Kavadi V, Dimopoulos MA, Hagemeister FB, Osborne BM, Fuller LM, Smith TL, Hess MA, McLaughlin PW, Cabanillas FF, Cox JD. Hodgkin's disease with lymphocyte predominance: long-term results based on current histopathologic criteria. Int J Radiat Oncol Biol Phys 43(2):329-34, 1999. e-Pub 1999. PMID: 10030257.
203. Hagemeister FB. Controversies in the management of early stage Hodgkin’s disease. Can Res Ther Control 7:259-265, 1999. e-Pub 1999.
204. Romaguera JE, Rodriguez MA, Hagemeister FB, McLaughlin P, Rodriguez J, Preti A, Younes A, Sarris AH, Cabanillas F. Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination. Invest New Drugs 17(2):187-92, 1999. e-Pub 1999. PMID: 10638491.
205. Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, Hagemeister F, Samuels B, Rodriguez A, Giralt S, Younes A, Przepiorka D, Claxton D, Cabanillas F, Champlin R. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16(12):3803-9, 1998. e-Pub 1998. PMID: 9850025.
206. Romaguera JE, Hagemeister FB, McLaughlin P, Rodriguez MA, Bachier C, Preti H, Sarris AH, Weber D, Younes A, Cabanillas F. Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma. Leuk Lymphoma 32(1-2):97-106, 1998. e-Pub 1998. PMID: 10037005.
207. Younes A, Romaguera J, Mesina O, Hagemeister F, Sarris AH, Rodriguez MA, McLaughlin P, Preti HA, Bachier C, Cabanillas F. Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma. Br J Haematol 103(3):678-83, 1998. e-Pub 1998. PMID: 9858216.
208. Vlachaki MT, Ha CS, Hagemeister FB, Fuller LM, Rodriguez MA, Hess MA, Tucker SL, Cabanillas F, Cox JD. Stage I Hodgkin disease: radiation therapy and chemotherapy at the University of Texas M. D. Anderson Cancer Center, 1996-1997. Radiology 208(3):739-47, 1998. e-Pub 1998. PMID: 9722855.
209. Liao Z, Ha CS, Fuller LM, Hagemeister FB, Cabanillas F, Tucker SL, Hess MA, Cox JD. Subdiaphragmatic stage I & II Hodgkin's disease: long-term follow-up and prognostic factors. Int J Radiat Oncol Biol Phys 41(5):1047-56, 1998. e-Pub 1998. PMID: 9719114.
210. Sarris, AH, Kliche KO, Peethambaram PP, Preti A, Jackow C, Mesina O, Hagemeister F, McLaughlin P, Rodriguez MA, Romaguera J, Fritsche H, Duvic M, Witzig T, Andreeff M, Cabanillas F. Serum Interleukin-10 (IL-10) and failure-free survival (FFS) of adult Hodgkin’s disease (HD). . Leukemia & Lymphoma 29(Suppl 1):32, 1998. e-Pub 1998.
211. Cabanillas F, Rodriguez-Diaz Pavon J, Hagemeister FB, McLaughlin P, Rodriguez MA, Romaguera JE, Dong K, Moon T. Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma. Ann Oncol 9(5):511-8, 1998. e-Pub 1998. PMID: 9653492.
212. Lopez-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Rodriguez MA, Romaguera JE, Younes A, Sarris AH, Preti HA, Pugh W, Lee MS. The clinical significance of molecular response in indolent follicular lymphomas. Blood 91(8):2955-60, 1998. e-Pub 1998. PMID: 9531606.
213. Bouvet M, Staerkel GA, Spitz FR, Curley SA, Charnsangavej C, Hagemeister FB, Janjan NA, Pisters PW, Evans DB. Primary pancreatic lymphoma. Surgery 123(4):382-90, 1998. e-Pub 1998. PMID: 9551063.
214. van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, Forman A, Romaguera J, Hagemeister F, Younes A, Bachier C, Sarris A, Sobocinski KS, Cox JD, Cabanillas F. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 91(4):1178-84, 1998. e-Pub 1998. PMID: 9454747.
215. Fuller LM, Mirza NQ, Palmer JL, Davis BR, Ha CS, Rodriguez MA, Hagemeister FB, Cabanillas F, McLaughlin P, Butler JJ, North LB, Martin RG. Hodgkin's disease: correlation of clinical characteristics with probabilities for negative lymphangiogram vs. negative laparotomy findings in patients with Stage I supradiaphragmatic presentations vs. those in patients with Stage II. Int J Radiat Oncol Biol Phys 40(2):377-86, 1998. e-Pub 1998. PMID: 9457824.
216. Romaguera JE, Rodriguez Diaz-Pavon J, Carias L, Hagemeister FB, McLaughlin P, Rodriguez MA, Sarris AH, Younes A, Preti A, Bachier C, Llerena E, Cabanillas F. Use of the international prognostic index and the tumor score to detect poor-risk patients with primary mediastinal large B-cell lymphoma: a study of 37 previously untreated patients. Leuk Lymphoma 28(3-4):295-306, 1998. e-Pub 1998. PMID: 9517501.
217. Meistrich ML, Wilson G, Mathur K, Fuller LM, Rodriguez MA, McLaughlin P, Romaguera JE, Cabanillas FF, Ha CS, Lipshultz LI, Hagemeister FB. Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease. J Clin Oncol 15(12):3488-95, 1997. e-Pub 1997. PMID: 9396402.
218. Younes, A, Rodriguez MA, McLaughlin P, North L, Sarris AH, Pate O, Hagemeister FB, Romaguera J, Preti A, Bachier C, Cabanillas F. Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin’s lymphoma. Leuk and Lymph 26:77-82, 1997. e-Pub 1997.
219. Vlachaki MT, Ha CS, Hagemeister FB, Fuller LM, Rodriguez MA, Besa PC, Hess MA, Brown B, Cabanillas F, Cox JD. Long-term outcome of treatment for Ann Arbor stage 1 Hodgkin's disease: patterns of failure, late toxicity and second malignancies. Int J Radiat Oncol Biol Phys 39(3):609-16, 1997. e-Pub 1997. PMID: 9336140.
220. Younes A, Rodriguez MA, McLaughlin P, North L, Sarris AH, Pate O, Hagemeister FB, Romaguera J, Preti A, Bachier C, Cabanillas F. Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma. Leuk Lymphoma 26(1-2):77-82, 1997. e-Pub 1997. PMID: 9250790.
221. Vlachaki MT, Hagemeister FB, Fuller LM, Besa PC, Hess MA, Brown B, Cabanillas F, Cox JD. Long-term outcome of treatment for Ann Arbor Stage I Hodgkin's disease: prognostic factors for survival and freedom from progression. Int J Radiat Oncol Biol Phys 38(3):593-9, 1997. e-Pub 1997. PMID: 9231684.
222. Rodriguez, J, Romaguera J, McLaughlin P, Hagemeister FB, Rodriguez M, Cabanillas F. Dose intensity as a treatment related variable in aggressive non-Hodgkin’s lymphoma. Blood 90:267b, 1997. e-Pub 1997.
223. Robbins WA, Meistrich ML, Moore D, Hagemeister FB, Weier HU, Cassel MJ, Wilson G, Eskenazi B, Wyrobek AJ. Chemotherapy induces transient sex chromosomal and autosomal aneuploidy in human sperm. Nat Genet 16(1):74-8, 1997. e-Pub 1997. PMID: 9140398.
224. Younes A, Ayoub JP, Sarris A, North L, Pate O, McLaughlin P, Rodriguez MA, Romaguera J, Hagemeister F, Bachier C, Preti A, Cabanillas F. Paclitaxel (Taxol) for the treatment of lymphoma. Ann Oncol 8 Suppl 1:129-31, 1997. e-Pub 1997. PMID: 9187446.
225. Younes A, Ayoub JP, Sarris A, Hagemeister F, North L, Pate O, McLaughlin P, Rodriguez MA, Romaguera J, Kurzrock R, Preti A, Bachier C, Smith T, Cabanillas F. Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. Br J Haematol 96(2):328-32, 1997. e-Pub 1997. PMID: 9029021.
226. Seymour JF, Talpaz M, Hagemeister FB, Cabanillas F, Kurzrock R. Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease. Am J Med 102(1):21-8, 1997. e-Pub 1997. PMID: 9209197.
227. Younes A, Cabanillas F, McLaughlin PW, Hagemeister FB, Farber C, Sarris A, Pate O, Myers J, Portlock C. Preliminary experience with paclitaxel for the treatment of relapsed and refractory Hodgkin's disease. Ann Oncol 7(10):1083-5, 1996. e-Pub 1996. PMID: 9037370.
228. McLaughlin P, Hagemeister FB, Romaguera JE, Sarris AH, Pate O, Younes A, Swan F, Keating M, Cabanillas F. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 14(4):1262-8, 1996. e-Pub 1996. PMID: 8648382.
229. Seymour JF, McLaughlin P, Fuller LM, Hagemeister FB, Hess M, Swan F, Romaguera J, Rodriguez MA, Besa P, Cox J, Cabanillas F. High rate of prolonged remissions following combined modality therapy for patients with localized low-grade lymphoma. Ann Oncol 7(2):157-63, 1996. e-Pub 1996. PMID: 8777172.
230. Younes A, Ayoub JP, Hagemeister FB, McLaughlin P, Sarris A, Rodriguez MA, Swan F, Jr, Romaguera JE, Martin J, Cabanillas F. No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule. J Clin Oncol 14(2):543-8, 1996. e-Pub 1996. PMID: 8636769.
231. Sarris AH, Younes A, McLaughlin P, Moore D, Hagemeister F, Swan F, Rodriguez MA, Romaguera J, North L, Mansfield P, Callendar D, Mesina O, Cabanillas F. Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 14(1):233-9, 1996. e-Pub 1996. PMID: 8558203.
232. Moore, DF, Huber MH, Lippman SM, Hagemeister FB. Merkel cell carcinoma: A second primary tumor following treatment for non-Hodgkin’s lymphoma. Cancer Bull 47(2):175-177, 1995. e-Pub 1995.
233. Moore DF, Swan F, Yau J, Rodriguez MA, McLaughlin P, Sarris A, Romaguera J, Younes A, Hagemeister FB, Cabanillas F. Cyclosporin plus doxorubicin, vincristine and etoposide in the treatment of refractory non-Hodgkin's lymphoma: a phase II study. Clin Oncol (R Coll Radiol) 7(5):300-3, 1995. e-Pub 1995. PMID: 8580055.
234. Rodriguez MA, Cabanillas FC, Hagemeister FB, McLaughlin P, Romaguera JE, Swan F, Velasquez W. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol 6(6):609-11, 1995. e-Pub 1995. PMID: 8573542.
235. Rodriguez MA, Cabanillas FC, Velasquez W, Hagemeister FB, McLaughlin P, Swan F, Romaguera JE. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 13(7):1734-41, 1995. e-Pub 1995. PMID: 7602363.
236. Suki S, Swan F, Jr, Tucker S, Fritsche HA, Redman JR, Rodriguez MA, McLaughlin P, Romaguera J, Hagemeister FB, Velasquez WS, et al. Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase. Leuk Lymphoma 18(1-2):87-92, 1995. e-Pub 1995. PMID: 8580834.
237. Rodriguez, Diaz-Pavon J, Cabanillas F, Majlis A, Hagemeister FB. Outcome of Hodgkin’s disease in elderly patients. Hemat Oncol 13:19-27, 1995. e-Pub 1995.
238. Przepiorka D, Nath R, Ippoliti C, Mehra R, Hagemeister F, Diener K, Dimopoulos M, Giralt S, Khouri I, Samuels B, et al. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. Leuk Lymphoma 17(5-6):427-33, 1995. e-Pub 1995. PMID: 7549833.
239. Younes A, Sarris A, Melnyk A, Romaguera J, McLaughlin P, Swan F, Rodriguez MA, Hagemeister F, Moore D, North L, et al. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. J Clin Oncol 13(3):583-7, 1995. e-Pub 1995. PMID: 7884419.
240. Fuller LM, Krasin MJ, Velasquez WS, Allen PK, McLaughlin P, Rodriguez MA, Hagemeister FB, Swan F, Jr, Cabanillas F, Palmer JL, et al. Significance of tumor size and radiation dose to local control in stage I-III diffuse large cell lymphoma treated with CHOP-Bleo and radiation. Int J Radiat Oncol Biol Phys 31(1):3-11, 1995. e-Pub 1995. PMID: 7527799.
241. Diaz-Pavon JR, Cabanillas F, Majlis A, Hagemeister FB. Outcome of Hodgkin's disease in elderly patients. Hematol Oncol 13(1):19-27, 1995. e-Pub 1995. PMID: 7750925.
242. Rodriguez J, Pugh WC, Romaguera JE, Luthra R, Hagemeister FB, McLaughlin P, Rodriguez MA, Swan F, Cabanillas F. Primary mediastinal large cell lymphoma is characterized by an inverted pattern of large tumoral mass and low beta 2 microglobulin levels in serum and frequently elevated levels of serum lactate dehydrogenase. Ann Oncol 5(9):847-9, 1994. e-Pub 1994. PMID: 7848887.
243. Seymour JF, Gagel RF, Hagemeister FB, Dimopoulos MA, Cabanillas F. Calcitriol production in hypercalcemic and normocalcemic patients with non-Hodgkin lymphoma. Ann Intern Med 121(9):633-40, 1994. e-Pub 1994. PMID: 7944070.
244. Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E, Cabanillas F. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 12(6):1169-76, 1994. e-Pub 1994. PMID: 8201379.
245. Velasquez WS, McLaughlin P, Fuller LM, Allen PK, Tucker SL, Swan F, Jr, Rodriguez MA, Hagemeister FB, Cabanillas FF. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis. Cancer 73(9):2408-16, 1994. e-Pub 1994. PMID: 7513251.
246. Hagemeister FB, Purugganan R, Fuller L, McLaughlin P, Swan F, Jr, Romaguera J, Rodriguez M, Cabanillas F. Treatment of early stages of Hodgkin's disease with novantrone, vincristine, vinblastine, prednisone, and radiotherapy. Semin Hematol 31(2 Suppl 3):36-43, 1994. e-Pub 1994. PMID: 8073308.
247. Hagemeister FB, Purugganan R, Podoloff DA, Hess M, Rodriguez MA, McLaughlin P, Swan F, Jr, Romaguera JE, Cabanillas F. The gallium scan predicts relapse in patients with Hodgkin's disease treated with combined modality therapy. Ann Oncol 5 Suppl 2:59-63, 1994. e-Pub 1994. PMID: 8204521.
248. Hagemeister FB, Khetan R, Allen P, McLaughlin P, Rodriguez MA, Swan F, Jr, Romaguera JE, Cabanillas F. Stage, serum LDH, and performance status predict disease progression and survival in HIV-associated lymphomas. Ann Oncol 5 Suppl 2:41-6, 1994. e-Pub 1994. PMID: 8204519.
249. McLaughlin P, Hagemeister FB, Swan F, Cabanillas F, Romaguera J, Rodriguez MA, Lee MS, Pate O, Sarris A, Younes A. Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement. Ann Oncol 5 Suppl 2:73-7, 1994. e-Pub 1994. PMID: 7515650.
250. McLaughlin P, Hagemeister FB, Swan F, Jr, Cabanillas F, Pate O, Romaguera JE, Rodriguez MA, Redman JR, Keating M. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 12(3):575-9, 1994. e-Pub 1994. PMID: 8120556.
251. Preti A, Hagemeister FB, McLaughlin P, Swan F, Rodriguez A, Besa P, Cox JD, Allen PK, Cabanillas F. Hodgkin's disease with a mediastinal mass greater than 10 cm: results of four different treatment approaches. Ann Oncol 5 Suppl 2:97-100, 1994. e-Pub 1994. PMID: 7515653.
252. Romaguera, JE, Sarris AH, Swan F, Younes A, Hagemeister FB, McLaughlin P, Rodriguez MA, Moore DF, Cabanillas F. Phase II study of 5-Fluorouracil by protracted infusion in patients with relapsing or refractory lymphoma. J Infusional Chemotherapy 4:173-176, 1994. e-Pub 1994.
253. FB: H. Hodgkin’s disease: Challenges in diagnosis, staging and treatment. Diagn Oncol 4:33-47, 1994. e-Pub 1994.
254. Romaguera JE, Rodriguez MA, Hagemeister FB, McLaughlin P, Swan F, Moore DF, Jr, Sarris AH, Younes A, Hill D, Cabanillas F. A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas. Invest New Drugs 12(3):217-22, 1994. e-Pub 1994. PMID: 7896540.
255. Hagemeister FB. Results of treatment of small non-cleaved cell lymphoma in patients without positive HIV serology. Leuk Lymphoma 10 Suppl:21-7, 1993. e-Pub 1993. PMID: 7683228.
256. Hagemeister FB. Are alkylating agents a necessary component in the therapy of Hodgkin's disease. Leuk Lymphoma 10 Suppl:91-7, 1993. e-Pub 1993. PMID: 7683230.
257. Dimopoulos MA, Cabanillas F, Lee JJ, Swan F, Fuller L, Allen PK, Hagemeister FB. Prognostic role of serum beta 2-microglobulin in Hodgkin's disease. J Clin Oncol 11(6):1108-11, 1993. e-Pub 1993. PMID: 8501496.
258. Robertson LE, Hall R, Keating MJ, Estey E, Kantarjian HM, McLaughlin P, Hagemeister FB, Plunkett W. High-dose cytosine arabinoside in chronic lymphocytic leukemia: a clinical and pharmacologic analysis. Leuk Lymphoma 10(1-2):43-8, 1993. e-Pub 1993. PMID: 8374522.
259. Liang JC, Bailey NM, Gabriel GJ, Kattan MW, Wang RY, Hagemeister FB, Cabanillas FF, Fuller LM. A new chemotherapy regimen for treatment of Hodgkin's disease associated with minimal genotoxicity. Leuk Lymphoma 9(6):503-8, 1993. e-Pub 1993. PMID: 7687918.
260. McLaughlin P, Cabanillas F, Hagemeister FB, Swan F, Jr, Romaguera JE, Taylor S, Rodriguez MA, Velasquez WS, Redman JR, Gutterman JU. CHOP-Bleo plus interferon for stage IV low-grade lymphoma. Ann Oncol 4(3):205-11, 1993. e-Pub 1993. PMID: 7682436.
261. Rodriguez MA, Fuller LM, Zimmerman SO, Allen PK, Brown BW, Munsell MF, Hagemeister FB, McLaughlin P, Velasquez WS, Swan F, Jr, et al. Hodgkin's disease: study of treatment intensities and incidences of second malignancies. Ann Oncol 4(2):125-31, 1993. e-Pub 1993. PMID: 8448080.
262. Spinolo JA, Jagannath S, Velasquez W, Spitzer G, Cabanillas F, Hagemeister F, Horwitz LJ, Dicke KA. Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease. Leuk Lymphoma 9(1-2):71-7, 1993. e-Pub 1993. PMID: 8477204.
263. Rodriguez J, Cabanillas F, McLaughlin P, Swan F, Rodriguez M, Hagemeister F, Romaguera J. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the 'tumor score'. Ann Oncol 3(9):711-7, 1992. e-Pub 1992. PMID: 1450060.
264. Hagemeister FB, Fuller L, McLaughlin P, Rodriguez M, Romaguera J, Swan F, Cabanillas F. NOVP and radiotherapy for early-staged Hodgkin's disease: an interim analysis. Ann Oncol 3 Suppl 4:87-90, 1992. e-Pub 1992. PMID: 1450086.
265. Hagemeister FB. Academia is not scutwork free. Ann Intern Med 116(9):779, 1992. e-Pub 1992. PMID: 1558358.
266. Redman JR, Cabanillas F, Velasquez WS, McLaughlin P, Hagemeister FB, Swan F, Jr, Rodriguez MA, Plunkett WK, Keating MJ. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol 10(5):790-4, 1992. e-Pub 1992. PMID: 1373760.
267. Spinolo JA, Cabanillas F, Dixon DO, Khorana SM, McLaughlin P, Velasquez WS, Hagemeister FB, Redman JR, Swan F, Jr. Therapy of relapsed or refractory low-grade follicular lymphomas: factors associated with complete remission, survival and time to treatment failure. Ann Oncol 3(3):227-32, 1992. e-Pub 1992. PMID: 1586621.
268. Woo SY, Fuller LM, Cundiff JH, Bondy ML, Hagemeister FB, McLaughlin P, Velasquez WS, Swan F, Jr, Rodriguez MA, Cabanillas F, et al. Radiotherapy during pregnancy for clinical stages IA-IIA Hodgkin's disease. Int J Radiat Oncol Biol Phys 23(2):407-12, 1992. e-Pub 1992. PMID: 1587764.
269. Cabanillas F, Velasquez WS, Hagemeister FB, McLaughlin P, Redman JR. Clinical, biologic, and histologic features of late relapses in diffuse large cell lymphoma. Blood 79(4):1024-8, 1992. e-Pub 1992. PMID: 1737086.
270. Hagemeister, Fredrick. Optimizing survival in Hodgkin’s disease. Hospital Medicine 28:91-109, 1992. e-Pub 1992.
271. Bodey G, Reuben A, Elting L, Kantarjian H, Keating M, Hagemeister F, Koller C, Velasquez W, Papadopoulos N. Comparison of two schedules of cefoperazone plus aztreonam in the treatment of neutropenic patients with fever. Eur J Clin Microbiol Infect Dis 10(7):551-8, 1991. e-Pub 1991. PMID: 1915397.
272. Romaguera JE, McLaughlin P, North L, Dixon D, Silvermintz KB, Garnsey LA, Velasquez WS, Hagemeister FB, Cabanillas F. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. J Clin Oncol 9(5):762-9, 1991. e-Pub 1991. PMID: 1707956.
273. Litam P, Swan F, Cabanillas F, Tucker SL, McLaughlin P, Hagemeister FB, Rodriguez MA, Velasquez WS. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma. Ann Intern Med 114(10):855-60, 1991. e-Pub 1991. PMID: 2014946.
274. Velasquez WS, Fuller LM, Jagannath S, Tucker SL, North LB, Hagemeister FB, McLaughlin P, Swan F, Redman JR, Rodriguez MA, et al. Stages I and II diffuse large cell lymphomas: prognostic factors and long-term results with CHOP-bleo and radiotherapy. Blood 77(5):942-7, 1991. e-Pub 1991. PMID: 1704805.
275. Robertson LE, Redman JR, Butler JJ, Osborne BM, Velasquez WS, McLaughlin P, Swan F, Rodriguez MA, Hagemeister FB, Fuller LM, et al. Discordant bone marrow involvement in diffuse large-cell lymphoma: a distinct clinical-pathologic entity associated with a continuous risk of relapse. J Clin Oncol 9(2):236-42, 1991. e-Pub 1991. PMID: 1988571.
276. McLaughlin P, Fuller L, Redman J, Hagemeister F, Durr E, Allen P, Holmes L, Velasquez W, Swan F, Cabanillas F. Stage I-II low-grade lymphomas: a prospective trial of combination chemotherapy and radiotherapy. Ann Oncol 2 Suppl 2:137-40, 1991. e-Pub 1991. PMID: 1710918.
277. Hagemeister FB, Fuller LM, Velasquez WS, McLaughlin P, Redman JR, Swan F, Rodriguez MA, North L, Dixon D, Silvermintz K, et al. Two cycles of MOPP and radiotherapy: effective treatment for stage IIIA and IIIB Hodgkin's disease. Ann Oncol 2(1):25-31, 1991. e-Pub 1991. PMID: 2009233.
278. Hagemeister FB, Cabanillas F, Velasquez WS, Meistrich ML, Liang JC, McLaughlin P, Redman JR, Romaguera JE, Rodriguez MA, Swan F, Jr, et al. NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease. Semin Oncol 17(6 Suppl 10):34-8; discussion 38-40, 1990. e-Pub 1990. PMID: 2259922.
279. Givens SS, Fuller LM, Hagemeister FB, Gehan EA. Treatment of lower torso stages I and II Hodgkin's disease with radiation with or without adjuvant mechlorethamine, vincristine, procarbazine, and prednisone. Cancer 66(1):69-74, 1990. e-Pub 1990. PMID: 2354411.
280. Romagurea JE, Velasquez WS, Silvermintz KB, Fuller LB, Hagemeister FB, McLaughlin P, Cabanillas F. Surgical debulking is associated with improved survival in stage I-II diffuse large cell lymphoma. Cancer 66(2):267-72, 1990. e-Pub 1990. PMID: 2369711.
281. Bonadonna, G, Cabanillas F, Hagemeister F, Ruit JB, Ho AD, Nissen NI, Hiddemann W, Gherlinzoni F. Mitoxantrone as monotherapy versus combination therapy: A panel discussion. Semin Oncol 17(Suppl 10):41-43, 1990. e-Pub 1990.
282. Lopez TM, Hagemeister FB, McLaughlin P, Velasquez WS, Swan F, Redman JR, Rodriguez MA, Tucker SL, Silvermintz K, Johnson J, et al. Small noncleaved cell lymphoma in adults: superior results for stages I-III disease. J Clin Oncol 8(4):615-22, 1990. e-Pub 1990. PMID: 2313330.
283. Hagemeister FB, Fesus SM, Lamki LM, Haynie TP. Role of the gallium scan in Hodgkin's disease. Cancer 65(5):1090-6, 1990. e-Pub 1990. PMID: 2302660.
284. Sen P, Bailey NM, Hagemeister FB, Liang JC. Induction of chromosome breaks and sister chromatid exchanges in patients with Hodgkin's disease by two combination chemotherapy regimens of different leukemogenic potential. Cancer Res 50(3):558-62, 1990. e-Pub 1990. PMID: 1688733.
285. Taylor KM, Jagannath S, Spitzer G, Spinolo JA, Tucker SL, Fogel B, Cabanillas FF, Hagemeister FB, Souza LM. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. J Clin Oncol 7(12):1791-9, 1989. e-Pub 1989. PMID: 2479719.
286. Fesus SM, Hagemeister FB, Manning J. Hodgkin disease in a patient with common variable immunodeficiency. Am J Hematol 32(2):138-42, 1989. e-Pub 1989. PMID: 2757010.
287. Swan F, Jr, Velasquez WS, Tucker S, Redman JR, Rodriguez MA, McLaughlin P, Hagemeister FB, Cabanillas F. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol 7(10):1518-27, 1989. e-Pub 1989. PMID: 2674337.
288. Velasquez WS, Jagannath S, Tucker SL, Fuller LM, North LB, Redman JR, Swan F, Hagemeister FB, McLaughlin P, Cabanillas F. Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data. Blood 74(2):551-7, 1989. e-Pub 1989. PMID: 2752132.
289. Cabanillas F, Pathak S, Grant G, Hagemeister FB, McLaughlin P, Swan F, Rodriguez MA, Trujillo J, Cork A, Butler JJ, et al. Refractoriness to chemotherapy and poor survival related to abnormalities of chromosomes 17 and 7 in lymphoma. Am J Med 87(2):167-72, 1989. e-Pub 1989. PMID: 2757057.
290. Jagannath S, Armitage JO, Dicke KA, Tucker SL, Velasquez WS, Smith K, Vaughan WP, Kessinger A, Horwitz LJ, Hagemeister FB, et al. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 7(2):179-85, 1989. e-Pub 1989. PMID: 2644397.
291. Fuller LM, Hagemeister FB. Two cycles of MOPP and definitive radiotherapy for stage IIIA and IIIB Hodgkin's disease. Recent Results Cancer Res 117:197-204, 1989. e-Pub 1989. PMID: 2602645.
292. Spinolo JA, Jagannath S, Dicke KA, Smith KE, Cabanillas F, Hagemeister FB, Horwitz LJ, McLaughlin P, Swan F, Spitzer G. High-dose combination chemotherapy with cyclophosphamide, carmustine, etoposide, and autologous bone marrow transplantation in 60 patients with relapsed Hodgkin's disease: the M. D. Anderson experience. Recent Results Cancer Res 117:233-8, 1989. e-Pub 1989. PMID: 2602646.
293. McLaughlin P, Velasquez WS, Redman JR, Yung WK, Hagemeister FB, Rodriguez MA, Cabanillas F. Chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin for parenchymal brain lymphoma. J Natl Cancer Inst 80(17):1408-12, 1988. e-Pub 1988. PMID: 3172268.
294. Cabanillas F, Pathak S, Trujillo J, Manning J, Katz R, McLaughlin P, Velasquez WS, Hagemeister FB, Goodacre A, Cork A, et al. Frequent nonrandom chromosome abnormalities in 27 patients with untreated large cell lymphoma and immunoblastic lymphoma. Cancer Res 48(19):5557-64, 1988. e-Pub 1988. PMID: 3416308.
295. Henkelmann GC, Hagemeister FB, Fuller LM. Two cycles of MOPP and radiotherapy for stage III1A and stage III1B Hodgkin's disease. J Clin Oncol 6(8):1293-302, 1988. e-Pub 1988. PMID: 3411342.
296. Cabanillas F, Pathak S, Trujillo J, Grant G, Cork A, Hagemeister FB, Velasquez WS, McLaughlin P, Redman J, Katz R, et al. Cytogenetic features of Hodgkin's disease suggest possible origin from a lymphocyte. Blood 71(6):1615-7, 1988. e-Pub 1988. PMID: 3370310.
297. Fuller LM, Hagemeister FB, North LB, McLaughlin P, Velasquez WS, Cabanillas F. The adjuvant role of two cycles of MOPP and low-dose lung irradiation in stage IA through IIB Hodgkin's disease: preliminary results. Int J Radiat Oncol Biol Phys 14(4):683-92, 1988. e-Pub 1988. PMID: 3280532.
298. Cabanillas F, Velasquez WS, McLaughlin P, Jagannath S, Hagemeister FB, Redman JR, Swan F, Rodriguez MA. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease. Semin Hematol 25(2 Suppl 2):47-50, 1988. e-Pub 1988. PMID: 3041599.
299. van der Velden JW, van Putten WLJ, Guinee VF, Pfeiffer R, van Leeuwen FE, van der Linden EAM, Vardomskaya I, Lane W, Durand M, Lagarde C, Hagemeister FB, Hagenbeek A, Eghbali H. Subsequent development of acute non-lymphocytic leukemia in patients treated for Hodgkin’s disease. Int J Cancer 42:252-255, 1988. e-Pub 1988.
300. Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 71(1):117-22, 1988. e-Pub 1988. PMID: 3334893.
301. Dixon DO, McLaughlin P, Hagemeister FB, Freireich EJ, Fuller LM, Cabanillas FF, Gehan EA. Reporting outcomes in Hodgkin's disease and lymphoma. J Clin Oncol 5(10):1670-2, 1987. e-Pub 1987. PMID: 3655864.
302. North LB, Fuller LM, Sullivan-Halley JA, Hagemeister FB. Regression of mediastinal Hodgkin disease after therapy: evaluation of time interval. Radiology 164(3):599-602, 1987. e-Pub 1987. PMID: 3112862.
303. Lee MS, Blick MB, Pathak S, Trujillo JM, Butler JJ, Katz RL, McLaughlin P, Hagemeister FB, Velasquez WS, Goodacre A, et al. The gene located at chromosome 18 band q21 is rearranged in uncultured diffuse lymphomas as well as follicular lymphomas. Blood 70(1):90-5, 1987. e-Pub 1987. PMID: 3297209.
304. McLaughlin P, Fuller LM, Velasquez WS, Butler JJ, Hagemeister FB, Sullivan-Halley JA, Dixon DO. Stage III follicular lymphoma: durable remissions with a combined chemotherapy-radiotherapy regimen. J Clin Oncol 5(6):867-74, 1987. e-Pub 1987. PMID: 3295130.
305. McLaughlin P, Cabanillas F, Hagemeister FB, Velasquez WS. Activity of bisantrene in refractory lymphoma. Cancer Treat Rep 71(6):631-3, 1987. e-Pub 1987. PMID: 3581102.
306. Hagemeister FB, Tannir N, McLaughlin P, Salvador P, Riggs S, Velasquez WS, Cabanillas F. MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. J Clin Oncol 5(4):556-61, 1987. e-Pub 1987. PMID: 3559649.
307. Cabanillas F, Hagemeister FB, McLaughlin P, Velasquez WS, Riggs S, Fuller L, Smith T. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 5(3):407-12, 1987. e-Pub 1987. PMID: 3819806.
308. Newell GR, Cabanillas FG, Hagemeister FJ, Butler JJ. Incidence of lymphoma in the US classified by the working formulation. Cancer 59(4):857-61, 1987. e-Pub 1987. PMID: 3802044.
309. Kalter SP, Riggs SA, Cabanillas F, Butler JJ, Hagemeister FB, Mansell PW, Newell GR, Velasquez WS, Salvador P, Barlogie B, et al. Aggressive non-Hodgkin's lymphomas in immunocompromised homosexual males. Blood 66(3):655-9, 1985. e-Pub 1985. PMID: 4027383.
310. Pillai GN, Hagemeister FB, Velasquez WS, Sullivan JA, Johnston DA, Butler JJ, Shullenberger CC. Prognostic factors for Stage IV Hodgkin's disease treated with MOPP, with or without bleomycin. Cancer 55(4):691-7, 1985. e-Pub 1985. PMID: 2578302.
311. Dixon C, Hagemeister F, Legha S, Bodey G. Pulmonary toxicity associated with spirogermanium. Cancer Treat Rep 68(6):907-8, 1984. e-Pub 1984. PMID: 6733705.
312. da Cunha MF, Meistrich ML, Fuller LM, Cundiff JH, Hagemeister FB, Velasquez WS, McLaughlin P, Riggs SA, Cabanillas FF, Salvador PG. Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy. J Clin Oncol 2(6):571-7, 1984. e-Pub 1984. PMID: 6547167.
313. Velasquez W, Fuller LM, Oh KK, Hagemeister FB, Sullivan JA, Manning JT, Shullenberger CC. Combined modality therapy in Stage III and Stage IIIE diffuse large cell lymphomas. Cancer 53(7):1478-83, 1984. e-Pub 1984. PMID: 6199100.
314. Perez-Soler R, McLaughlin P, Velasquez WS, Hagemeister FB, Zornoza J, Manning JT, Fuller LM, Cabanillas F. Clinical features and results of management of superior vena cava syndrome secondary to lymphoma. J Clin Oncol 2(4):260-6, 1984. e-Pub 1984. PMID: 6368759.
315. Hagemeister, F, LM: F. Lymphoma and Hodgkin’s disease. Consultant 24:128-148, 1984. e-Pub 1984.
316. Tannir NM, Spitzer G, Zander AR, Jagannath S, Kanojia M, Vellekoop L, McLaughlin P, Hagemeister FJ, Dicke KA. High-dose chemoradiotherapy and bone marrow transplantation in patients with refractory lymphoma. Eur J Cancer Clin Oncol 19(8):1091-6, 1983. e-Pub 1983. PMID: 6352279.
317. Tannir N, Hagemeister F, Velasquez W, Cabanillas F. Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease. J Clin Oncol 1(7):432-9, 1983. e-Pub 1983. PMID: 6199478.
318. Vlasak MC, Martin RG, Fuller LM, Hagemeister FB, da Cunha F, Shullenberger CC. Clinical staging of Hodgkin’s disease. Results of staging laparotomy. Cancer Bulletin 35:209-214, 1983. e-Pub 1983.
319. Fuller LM, Hagemeister FB. Diagnosis and management of Hodgkin's disease in the adult. Cancer 51(12 Suppl):2469-76, 1983. e-Pub 1983. PMID: 6687831.
320. Hagemeister FB. Treatment options for stage III Hodgkin’s disease. Cancer Bulletin 35:224-229, 1983. e-Pub 1983.
321. FB: H. New approaches to management of stage IV Hodgkin’s disease. Cancer Bulletin 35:230-232, 1983. e-Pub 1983.
322. Fuller LM, FB: H. Hodgkin’s disease stage I and II. Management considerations and results in adults. Cancer Bulletin 35:218-23, 1983. e-Pub 1983.
323. Thomas JL, Bernardino ME, Vermess M, Barnes PA, Fuller LM, Hagemeister FB, Doppman J, Fisher RI, Longo DL. EOE-13 in the detection of hepatosplenic lymphoma. Radiology 145(3):629-34, 1982. e-Pub 1982. PMID: 6292995.
324. Hagemeister FB, Fuller LM, Sullivan JA, Johnston D, North L, Butler JJ, Velasquez WS, Shullenberger CC. Treatment of patients with stages I and II nonmediastinal Hodgkin's disease. Cancer 50(11):2307-13, 1982. e-Pub 1982. PMID: 6754064.
325. Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ. IMVP-16: An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 60(3):693-7, 1982. e-Pub 1982. PMID: 7104493.
326. Hagemeister FB, Fuller LM, Velasquez WS, Sullivan JA, North L, Butler JJ, Johnston DA, Shullenberger CC. Stage I and II Hodgkin's disease: Involved-field radiotherapy versus extended-field radiotherapy versus involved-field radiotherapy followed by six cycles of MOPP. Cancer Treat Rep 66(4):789-98, 1982. e-Pub 1982. PMID: 7074649.
327. Thomas JL, Barnes PA, Bernardino ME, Hagemeister FB. Limited CT studies in monitoring treatment of lymphoma. AJR Am J Roentgenol 138(3):537-9, 1982. e-Pub 1982. PMID: 7039271.
328. North LB, Fuller LM, Hagemeister FB, Rodgers RW, Butler JJ, Shullenberger CC. Importance of initial mediastinal adenopathy in Hodgkin disease. AJR Am J Roentgenol 138(2):229-35, 1982. e-Pub 1982. PMID: 6976723.
329. Fuller, LM, FB: H. Effective use of radiotherapy for stage I, II and III Hodgkin’s disease. Cancer Bulletin 34:260-263, 1982. e-Pub 1982.
330. Hagemeister FB, Fuller LM, Sullivan JA, North L, Velasquez W, Conrad FG, McLaughlin P, Butler JJ, Shullenberger CC. Treatment of stage I and II mediastinal Hodgkin disease. A comparison of involved fields, extended fields, and involved fields followed by MOPP in patients staged by laparotomy. Radiology 141(3):783-9, 1981. e-Pub 1981. PMID: 6895415.
331. Osborne BM, Hagemeister FB, Butler JJ. Extranodal gastrointestinal sinus histiocytosis with massive lymphadenopathy. Clinically presenting as a malignant tumor. Am J Surg Pathol 5(6):603-11, 1981. e-Pub 1981. PMID: 7325277.
332. Rodgers RW, Fuller LM, Hagemeister FB, Johnston DA, Sullivan JA, North LB, Butler JJ, Velasquez WS, Conrad FG, Shullenberger CC. Reassessment of prognostic factors in stage IIIA and IIIB Hodgkin's disease treated with MOPP and radiotherapy. Cancer 47(9):2196-203, 1981. e-Pub 1981. PMID: 7226112.
333. Hagemeister FB. A case of Burkitt’s lymphoma. Cancer Bulletin 33:295-297, 1981. e-Pub 1981.
334. Fuller LM, Madoc-Jones H, Hagemeister FB, Jr, Rodgers RW, North LB, Butler JJ, Martin RG, Gamble JF, Shullenberger CC. Further follow-up of results of treatment in 90 laparotomy-negative stage I and II Hodgkin's disease patients: significance of mediastinal and non-mediastinal presentations. Int J Radiat Oncol Biol Phys 6(7):799-808, 1980. e-Pub 1980. PMID: 7204116.
335. Hagemeister FB, Jr, Buzdar AU, Luna MA, Blumenschein GR. Causes of death in breast cancer: an autopsy study. Cancer 46(1):162-67, 1980. e-Pub 1980. PMID: 7388758.
336. Manoukian G, Hagemeister F, McLaughline P, Fayad L, Samaniego F, Goy A, Romaguera J, Pro B, Hess M, Cabanillas F, Khouri I, Rodriguez A. Rituximab, Fludarabine, Mitoxantrone, and Dexamethasone (RFND) for Patients with Relapsed Indolent Lymphoma. Journal of Clinical Oncology.
337. Rodriguez A, Fayad L, Dang N, Forman A, Goy A, Hagemeister F, McLaughlin P, Medeiros J, Nakamura H, Pro B, Romaguera J, Samaniego F, Samuels B, Sarris A, Younes A, Lu B, Deitcher S, and Cabanillas F. Phase 2 Study of Vincristine Sulfate Liposomal Injection (Maqibo) in Substitution of Conventional Vincristine in CHOP Rituximab for Patients with Untreated Aggressive Non-Hodgkin's Lymphoma.

Invited Articles

1. Hagemeister FB. Maintenance and Consolidation Strategies in Non-Hodgkin's Lymphoma: A Review of the Data. Curr Oncol Rep 12(6):395-401, 2010. e-Pub 2010. PMID: 20820960.
2. Manoukian G, Hagemeister F. Denileukin diftitox: a novel immunotoxin. Expert Opin Biol Ther 9(11):1445-51, 2009. e-Pub 2009. PMID: 19817678.
3. Hagemeister FB. Controversies in management of follicular lymphoma: Diagnosis, choices of initial treatment, and new directions of therapy. MedscapeCME Oncology. e-Pub 2009.
4. Hagemeister F, Manoukian G. Bendamustine in the treatment of non-Hodgkin's lymphomas. Onco Targets Ther 2:269-79, 2009. e-Pub 2009. PMID: 20616914.
5. Friedberg JW, Hagemeister FB, Levine AM. Combination Treatment Approaches and Novel Therapies for Lymphoma. Clin Adv Hematol Oncol 5(8) suppl 12(8 Suppl 12):4-20, 2007. e-Pub 2007. PMID: 18154235.
6. Hagemeister FB. Overview of the Treatment of Follicular Lymphoma. Clinical Advances in Hematology & Oncology 5(8):3-6, 2007. e-Pub 2007.
7. Hagemeister FB. Hodgkin's lymphoma in younger patients: Lessons learned on the road to success. Oncology (Williston Park) 21(4):434-42, 2007. e-Pub 2007. PMID: 17474345.
8. Hagemeister FB. The FLIPI and the R-FLIPI: Are we finally ready to use them in clinical trials?. Am J Hematol/Onc 6(6):364-68, 2007. e-Pub 2007.
9. Hagemeister FB. Hodgkin’s lymphoma in the elderly: Who is “older” and is the disease really worse in older patients?. Oncology 21(8):996-1002, 2007. e-Pub 2007.
10. Hagemeister FB, McLaughlin P. Exploring treatment options in non-Hodgkin's lymphoma. The American Journal of Oncology Review 5 (3):Suppl 4, 2006. e-Pub 2006.
11. Hagemeister FB. Treatment for Patients with Indolent Lymphomas: Is There a “Best” Regimen?. The American Journal of Oncology Review 4(5), 2005. e-Pub 2005.
12. Hagemeister FB. Advances in the Treatment of Non-Hodgkin Lymphoma: Interleukin-2 Fusion Toxin. A review of selected abstracts from the 2004 Annual Meeting of the American Society of Hematology (Commentary). Clinical Advances in Hematology & Oncology 3 (3):Suppl 2, 2005. e-Pub 2005.
13. Hagemeister FB. Mantle cell lymphoma: non-myeloablative versus dose-intensive therapy. Leuk Lymphoma 44 Suppl 3:S69-75, 2003. e-Pub 2003. PMID: 15202528.
14. Hagemeister FB. Mantle cell lymphoma: non-myeloablative versus dose-intensive therapy. Leuk Lymphoma 44 Suppl 3:S69-75, 2003. e-Pub 2003. PMID: 15202528.
15. Hagemeister FB. Potential Uses of Ontak (denileukin diftitox) in Hematologic Tumors and Graft-Versus-Host Disease. The American Journal of Oncology Review 2(Suppl 1):8-11, 2003. e-Pub 2003.
16. Hagemeister FB, Diehl V. The role of ifosfamide in cytoreduction, stem cell mobilization and high-dose therapy in relapsed/refractory malignant lymphomas. Eur J Haematol Suppl 64:1-2, 2001. e-Pub 2001. PMID: 11486394.

Review Articles

1. Khan M, Hagemeister F, Wang M, Ahmed S. A review of pathobiology and therapies for classic Hodgkin lymphoma. Blood Rev 55:100949, 2022. e-Pub 2022. PMID: 35396126.
2. Khan M, Samaniego F, Hagemeister FB, Iyer SP. Emerging Therapeutic Landscape of Peripheral T-Cell Lymphomas Based on Advances in Biology: Current Status and Future Directions. Cancers (Basel) 13(22), 2021. e-Pub 2021. PMID: 34830782.
3. Hagemeister F. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 70(3):261-72, 2010. e-Pub 2010. PMID: 20166765.
4. Soriano AO, Thompson MA, Admirand JH, Fayad LE, Rodriguez MA, Romaguera JE, Hagemeister FB, Pro B. Follicular Dendritic Cell Sarcoma: A Report of 14 Cases and a Review of the Literature. Am J Hematol 82(8)(8):725-28, 2007. e-Pub 2007. PMID: 17373675.
5. Hagemeister F, Cabanillas F, Coleman M, Gregory SA, Zinzani PL. The role of mitoxantrone in the treatment of indolent lymphomas. Oncologist 10:150-9, 2005. e-Pub 2005. PMID: 15709217.
6. Hagemeister F, Huen A. The status of allopurinol in the management of tumor lysis syndrome: a clinical review. Cancer 11 Suppl 1:S1-10, 2005. e-Pub 2005. PMID: 15835720.
7. Romaguera JE, Hagemeister FB. Lymphoma of the colon. Curr Opin Gastroenterol 21(1):80-84, 2005. e-Pub 2005. PMID: 15687889.
8. Seymour JF, Pro B, Fuller LM, Manning JT, Hagemeister FB, Romaguera J, Rodriguez MA, Ha CS, Smith TL, Ayala A, Hess M, Cox JD, Cabanillas F, McLaughlin P. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. J Clin Oncol 21(11):2115-22, 2003. e-Pub 2003. PMID: 12775737.
9. Hagemeister FB. Rituximab and chemotherapy for aggressive lymphomas: a significant advance in therapy. Clin Adv Hematol Oncol 1(2):120-5, 2003. e-Pub 2003. PMID: 16224391.
10. Hagemeister FB. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Cancer Chemother Pharmacol 49 Suppl 1:S13-20, 2002. e-Pub 2002. PMID: 12042984.
11. Hagemeister FB, Donato M. Ifosfamide-based chemotherapy regimens in treatment of lymphoma: the M.D. Anderson experience. Eur J Haematol Suppl 64:8-13, 2001. e-Pub 2001. PMID: 11486405.
12. Hagemeister FB. The role of ifosfamide in the treatment of lymphomas. Leuk Lymphoma 34(5-6):433-41, 1999. e-Pub 1999. PMID: 10492066.
13. Cather JC, Jackow C, Yegge J, Hagemeister F, Duvic M. Mycosis fungoides with focal segmental glomerular sclerosis and nephrotic syndrome. J Am Acad Dermatol 38(2 Pt 2):301-5, 1998. e-Pub 1998. PMID: 9486702.
14. Hagemeister FB. Treatment of small non-cleaved cell lymphoma in the adult. Biomed Pharmacother 50(9):433-41, 1996. e-Pub 1996. PMID: 8991114.
15. Hagemeister FB. Hodgkin's disease: the next decade. Leuk Lymphoma 21(1-2):53-61, 1996. e-Pub 1996. PMID: 8907270.
16. Hagemeister FB. Low-grade lymphomas: new entities and treatment concepts. Med Oncol 12(3):131-42, 1995. e-Pub 1995. PMID: 8852395.
17. Fuller LM, Hagemeister FB, Velasquez WS, Sullivan MP. Hodgkin's disease and non-Hodgkin's lymphomas. Compr Ther 15(8):3-11, 1989. e-Pub 1989. PMID: 2670408.
18. Hagemeister FB. Prognostic factors in decision-making in the clinical management of Hodgkin's disease. Hematol Oncol 6(3):257-69, 1988. e-Pub 1988. PMID: 3042583.

Other Articles

1. Davis AF, Hagemeister FB Facts on Mantel Cell Lymphoma. Lymphoma Research Foundation, 2007.

Editorials

1. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15(1):69-77, 2014. PMID: 24332512.

Abstracts

1. Chihara D, Ahmed MA, Oki Y, Westin JR, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu S, Rodriguez A, Fowler N, Wang M, Fayad LE, Davis RE, Nastoupil L. Management Strategies and Outcomes for Very Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Blood 126(23):1502, 2015. e-Pub 2015.
2. Chihara D, Fanale MA, Noorani M, Westin JR, Nastoupil L, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu S, Rodriguez A, Wang M, Fowler N, Miranda RN, Hosing CM, Yago Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma. Blood 126(23):2738, 2015. e-Pub 2015.
3. Chihara D, Fanale MA, Noorani M, Westin JR, Nastoupil L, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu S, Rodriguez A, Wang M, Fowler N, Miranda RN, Hosing CM, Yago Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL 126(23):3984, 2015. e-Pub 2015.
4. Nieto Y, Bassett R, Anderlini P, Hosing CM, Alousi AM, Popat UR, Andersson BS, Valdez BC, Shpall EJ, Ahmed S, Qazilbash M, Guillermo M, Oki Y, Fanale M, Hagemeister F, Dabaja BS, Pinnix CC, Milgrom SA, Tewari P, Champlin RE, Jones R. Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem-Cell Transplant (ASCT) without Post-ASCT Maintenance, in Hodgkins Lymphoma Patients at High Risk of Post-Transplant Recurrence Comparison with a Concurrent Matched Cohort Treated with BEAM. Blood 126(23):1980, 2015. e-Pub 2015.
5. Fanale, MA, Wang Z, Ma W, Oki Y, Hagemeister, F, Fayad, LE, Fowler, N, Romaguera JE, Shah N, Chuang HH, Lei F, Horowitz SB, Chihara D, Wesson E, Hutto T, Ruben C, Samaniego F, Muzzafar T, Piekarz R, Davis RE. Gene Expression Profiling for Molecular Features of Response in a Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas. Blood 126(23):2705, 2015. e-Pub 2015.
6. Ahmed MA, Oki Y, Noorani M, Nastoupil L, Fayad LE, Hagemeister FB, Rosriguez A, Davis RE, Westin J. The Clinical Outcome of Newly Diagnosed Patients >60 Years of Age with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Standard or Liposomal Chemotherapies. Blood 126(23):3965, 2015. e-Pub 2015.
7. Wang Y, Wagner-Bartak N, Zhou S, Fowler N, Dela Rosa ML, Zhao D, Romaguera JE, Neelapu JS, Hagemeister FB, Fanale MA, Oki Y, Shah J, Thomoas SK, Hosing CM, Zhang L, Badillo M, Chen W, Cai Q, Zou D, Champlin RE, Fayad LE, Lee HJ, Wang M. Lenalidomide Plus Rituximab for Relapsed or Refractory Diffuse Large B-Cell, Follicular and Transformed Lymphoma: Final Data Analysis of a Phase 2 Trial. Blood 123(23):3969, 2015. e-Pub 2015.
8. Nieto Y, Valdez BC, Thall PF, Wei W, Jones R, Hosing CM, Ahmed S, Popat UR, Shpall EJ, Qazilbash M, Gulbis AM, Anderlini P, Shah N, Bashir Q, Alousi AM, Oki Y, Hagemeister FB, Champlin RE, Andersson BS. Double Epigenetic Modulation of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Refractory or Poor-Risk Relapsed Lymphoma. Blood 126(23):1992, 2015. e-Pub 2015.
9. Fowler N, Pinto RM, Cheah CY, Neelapu S, Turturro F, Hagemeister FB, Romaguera JE, Fanale MA, Fayad LE, Forbes S, Khan J, Feng L, Samaniego F, Nastoupil L. A Phase I Study of Lenalidomide Plus a Next Generation Anti-CD20 Antibody, Obinutuzumab, in Relapsed Indolent Lymphoma. Blood 126(23):1502, 2015. e-Pub 2015.
10. Cheah CY, Chihara D, Sevin A, Horowitz S, Oki Y, Fowler N, Neelapu S, Nastoupil L, Turturro F, Hagemeister F, Westin J, Romaguera J, Fayad L, Samaniego F, Fanale MA. Patients with Classical Hodgkin Lymphoma Failing Brentuximab Vedotin have Brief Responses to Salvage Therapies and Limited Survival. HAA Annual Scientific Meeting 2015, 2015. e-Pub 2015.
11. Phansalkar K, Ahmed MA, Fowler N, Ma L, Noorani M, Lee ST, Feng L, Hagemeister FB, Romaguera JE, Fayad L, Rodriguez A, Samaniego F, Fanale MA, Wang M, Oki Y, Tuturro F, Westin JR, Nastoupil LJ, Kwak LW, Davis RE, Neelapu S. R-Bendamustine Vs R-CHOP As Initial Treatment for Advanced Stage Low Grade Follicular Lymphoma: A Matched-Pair Analysis. Blood 124:3048, 2014. e-Pub 2014.
12. Fanale MA, Westin JR, Fowler N, Neelapu SS, Hagemeister FB, Rodriguez MA, Younes A. A Phase I Study Of Panobinostat In Combination With ICE (Ifosfamide, Carboplatin and Etoposide) In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma (cHL). Blood (ASH Annual Meeting Abstracts) 122(21):252, 2013. e-Pub 2013.
13. Thall PF, Valdez BC, Hosing CM, Ahmed S, Jones RB, Shah N, Anderlini P, Qazilbash MH, Popat UR, Bashir Q, Shpall EJ, Alousi A, Kebriaei P, Fox P, Bassett R, Chancoco C, Oki Y, Fanale MQ, Fowler N, Hagemeister FB, Romaguera JE, Champlin RE, Andersson BS. Vorinostat (SAHA) Combined With High-Dose Gemcitabine/Busulfan/Melphalan (SAHA/Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Patients With Refractory Lymphomas. Blood (ASH Annual Meeting Abstracts) 122(21):2095, 2013. e-Pub 2013.
14. Feng L, Oki Y, Qazilbash M, Muzzafar T, Weber DM, Fowler N, Popat UR, Thomas SK, Fanale MA, Nieto Y, Shah N, Bashir Q, Hagemeister FB, Orlowski R, Shah JJ. Plasmablastic Lymphoma: 28 Patient Single Institution Experience. Blood (ASH Annual Meeting Abstracts) 122(21):4310, 2013. e-Pub 2013.
15. Noorani M, Davis RE, Neelapu SS, Rodriguez AM, Hagemeister FB, Fowler N, Wang M, Fanale MA, Samaniego F, Dabaja BS, Pinnix C, Kwak LW, Romaguera JE, Khouri I, Westin JR, Fayad LE. Double Hit Lymphoma: M.D. Anderson Experience. Blood (ASH Annual Meeting Abstracts) 122(21):1776, 2013. e-Pub 2013.
16. Romaguera JE, Kwak LW, Hagemeister FB, Rodriguez MA, Oki Y, Westin JR, Turturro F, Overman MJ, Neelapu SS, Fowler N, Fayad LE. Long-Term Remissions Of Patients With Follicular Lymphoma Grade 3 Treated With Rituximab, Cyclophospamide, Doxorubicine, Vincristine and Prednisone (R-CHOP). Blood (ASH Annual Meeting Abstracts) 122(21):3028, 2013. e-Pub 2013.
17. Hagemeister FB, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A, Dang NH, Forman A, McLaughlin P, Pro B, Romaguera JE, Samaniego F, Silverman JA, Sarris AH, and Cabanillas F. Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo®) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin’s Lymphomas. Blood (ASH Annual Meeting Abstracts) 122(21):3033, 2013. e-Pub 2013.
18. Romaguera JE, Fanale MA, Samaniego F, Fayad LE, Hagemeister FB, McLaughlin P, Rodriguez MA, Weaver P, Hartig K, Badillo M, Kwak LW, Younes A, Pro B, and Wang M. Phase II Trial Of Bortezomib In Combination With Fractionated Cyclophosphamide and Rituximab (BCR) For Relapsed/Refractory Mantle Cell Lymphoma (MCL). Blood (ASH Annual Meeting Abstracts) 122(21):5122, 2013. e-Pub 2013.
19. Oki Y, Westin J, Fowler N, Neelapu S, Hagemeister F, McLaughlin P, Kwak L, Romaguera J, Fanale M, Younes A, Rodriguez MA, Orlowski R, Wang M, Ouzanian S, Smaniego F, and Fayad L. R-HCVAD alternating with R-methotrexate cytarabine in younger patients (pts) with IH and high-risk age adjusted-ipi- DLBCL. Blood (ASH Annual Meeting Abstracts) 120(21), 2012. e-Pub 2012.
20. Oki Y, Chuang H, Chasen B, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez A, Neelapu S, Samaniego F, Kwak L, and Younes A. The prognostic value of interim PET scan in patients with classical Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts) 120(21), 2012. e-Pub 2012.
21. Fowler N, Neelapu S, Hagemeister F, McLaughlin P, Kwak L, Romaguera J, Fanale M, Fayad L, Orlowski R, Wang M, Turturro F, Oki Y, Lacerte L, and Samaniego F. Lenalidomide and rituximab for untreated indolent lymphoma: Final results of a phase II study. Blood (ASH Annual Meeting Abstracts) 120(21), 2012. e-Pub 2012.
22. Fanale M, Lai C, Rimes S, Ramirez M, Hagemeister F, Fowler N, Younes A, Fayad L, Rodriguez MA, Turturro F, Samaniego F, Romaguera J, Levin V, Horowitz S, Woolery J, Milbourne A. Positive maternal-fetal outcomes with treatment of lymphoma during pregnancy: UT MD Anderson Cancer Center Prospective. Blood (ASH Annual Meeting Abstracts) 120(21), 2012. e-Pub 2012.
23. Westin J, Chu F, Fayad L, Kwak L, Fowler N, Romaguera J, Hagemeister FB, Fanale M, Samaniego F, Allen R, Feng L, Baladandayuthapani V, Rotem-Yehudar R, and Neelapu S. Phase II safety and efficacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab in patients with relapsed follicular lymphoma. Blood (ASH Annual Meeting Abstracts) 120(21), 2012. e-Pub 2012.
24. Dabaja B, Phan J, Medeiros J, Hagemeister F, Chuang H, Fayad L, Shihadeh F, Allen, P, Wogan C, and Maria A Rodriguez MA. Clinical Implications of PET-Negative Residual Disease At the Completion of Chemotherapy for Diffuse Large B-Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 118(21), 2011. e-Pub 2011.
25. Younes A, Copeland A, Fanale M, Fayad L, Romaguera J, Kwak L, Neelapu S, Hagemeister F, Pro B, Faria S, Ji Y, Berry D, Buglio D, and Medeiros J. Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma. Blood (ASH Annual Meeting Abstracts) 118(21), 2011. e-Pub 2011.
26. Vadhan-Raj S, Spasojevic I, Zhou X, Romaguera J, Fanale M, Fayad L, Fowler N, Huen A, Hagemeister F, Rodriguez A, Neelapu S, Samaniego F, Younes A, Kwak L. Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multiday Chemotherapy Regimen of Cyclophosphamide, Doxorubicon, vincristine, prednisone, +/- Rituxan (R/CHOP): Randomized, Double-blind, Placebo-Controlled Study. Blood (ASH Annual Abstracts) 118(21), 2011. e-Pub 2011.
27. Fowler N, Neelapu S, Fanale M, Rodriguez M, Pro B, Hagemeister F, Younes A, Shah J, Kwak L, Rodriguez D, McLaughlin P. Phase II Study with R-FND Followed by 90-Y Ibritumomab Tiuxetan Radioimmunotherapy and Rituximab Maintenance for Untreated High-Risk Follicular Lymphoma. Blood (ASH Annual Meeting Abstracts) 118(21), 2011. e-Pub 2011.
28. Samaniego F, Wise J, Fayad L Fanale M, Hagemeister F, Selvaraj V, Goldenberg DM, Kwak LW, and Berkova Z. Anti-CD74 Antibody hLL1 Is Associated with Lymphoma and Chronic Lymphocytic Leukemia Cell Effects In Vivo. Blood (ASH Annual Meeting Abstracts) 118(21), 2011. e-Pub 2011.
29. Vadhan-Raj S, hagemeister F, Fayad L, Zhou X, O'Roark S, Ames K, Rodriguez MA, Fanale M, Pro B, Johnson M, McLaughlin P, Bueso-Ramos C, Younes A, Kwak L, and Romaguera J. Randomized, double-blind, placebo-controlled, dose and schedule-finding study of AMG 531 in chemotherapy-induced thrombocytopenia (CIT): Results of a phase I/II study. American Society of Hematology 52nd Annual Meeting Abstracts 116(21), 2010. e-Pub 2010.
30. Younes A, Copeland A, Fanale M, Hagemeister F, Fayad L, Pro B, Faria S, Ji Y, Medeiros J, Berry D, and Buglio D. Phase I/II study of the novel combinationof panobinostat (LBH589) and everolimus (RAD001) in relapsed/refractory Hodgkin and non-Hodgkin lymphoma. American Society of Hematology 52nd Annual Meeting Abstracts 116(21), 2010. e-Pub 2010.
31. Okoroji G, Silva L, Saliba R, Korbling M, McLaughlin P, Hosing C, Anderlini P, Alousi A, de Lima M, Kebriael P, Popat U, Qazilbash M, Fayad L, Samaniego F, Fowler N, Champlin R, Hagemeister F, and Khouri I. Outcome in follicular lymphoma (FL) patients (pts) relapsing after autologous stem cell transplantation (ASCT): Allografting vs conventional therapy. American Society of Hematology 52nd Annual Meeting Abstracts 116(21), 2010. e-Pub 2010.
32. Thomas D, O'Brien S, Cortes J, Faderl S, Wierda W, Garcia-Manero G, Jabbour E, Ferrajoli A, Verstovsek S, Burger J, Garris R, Romaguera J, Hagemeister F, and Kantarjian H. Long-term outocme for De Novo or minimaly treated Burkitt-type lymphoma/leukemia (BL/B-ALL) after therapy with hyper-CVAD and rituximab. American Society of Hematology 52nd Annual Meeting Abstracts 116(21), 2010. e-Pub 2010.
33. Hamlin P, Rodriguez M, Noy A, Portlock C, Straus D, McLaughlin P, Pro B, Fayad L, Hagemeister F, Wegner B, Dumitrescu O, Tasker N, Moskowitz C, and Zelenetz A. Final results of a Phase II study of sequential R-CHOP and yttrium-90 ibritumumab tiuxetan (RIT) for elderly high risk patients with untreated diffuse large B-cell lymphoma (DLBCL). American Society of Hematology 52nd Annual Meeting Abstracts 116(21), 2010. e-Pub 2010.
34. Fanale M, Lai C, McLaughlin P, Romaguera J, Fayad L, Hagemeister F, Samaniego F, Rodriguez MA, Neelapu S, Shah J, Kwak L, Dong W, Reed V, Dabaja B, Popat U, Younes A. Outocmes of nodular lymphomcyte predominant Hodgkin's lymphoma (NLPHL) patients treated with R-CHOP. American Society of Hematology 52nd Annual Meeting Abstracts 116(21), 2010. e-Pub 2010.
35. Batty N, Ghonimi E, Feng L, Younes A, Rodriguez MA, Wager E, Martinez F, Wang M, McLaughlin P, Fowler N, and Hagemeister F. Blood transfusion and erythropoiesis stimulating agents (ESAs) use in patients with diffuse large B-cell lymphoma (DLBCL). American Society of Hematology 52nd Annual Meeting Abstracts 116(21), 2010. e-Pub 2010.
36. Fowler N, McLaughlin P, Hagemeister FB, Kwak LW, Fanale MA, Neelapu SS, Fayad L, Orlowski RZ, Wang M, Samaniego F. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. ASCO Annual Meeting Abstracts, 2010. e-Pub 2010.
37. Westin JR, Thompson MA, Cataldo VD, Toth BB, Sanjorjo P, Bourgeois S, Jimenez C, Murphy WA, Kwak LW, Hagemeister FB. The effect of zoledronic acid on the prevention of bone loss in lymphoma patients receiving first-line therapy. 2010 ASCO Annual Meeting Abstracts, 2010. e-Pub 2010.
38. Manoukian GE, Hagemeister FB, McLaughlin P, Fayad L, Samaniego F, Goy A, Romaguera JE, Pro B, Cabanillas F, Rodriguez MA. Rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND) for patients with relapsed indolent B-cell lymphoma (RIL). 2010 ASCO Annual Meeting Abstracts, 2010. e-Pub 2010.
39. Perini GF, Romaguera JE, Rodriguez MA, Pro B, Younes A, Fowler N, Hagemeister FB, Samaniego F, Kwak LW, Fayad L. Diffuese large b-cell lymphoma (DLBCL) with bone marrow (BM) involvement, clinical presentation, central nervous system (CNS) relapses, and outcome of 121 patients treated at MD Anderson Cancer Center. 2010 ASCO Meeting Abstracts, 2010. e-Pub 2010.
40. Batty N, Hagemeister FB, Romaguera JE, Rodriguez MA, McLaughlin P, Samaniego F, Copeland A, Dabaja BS, Younes A. ABVD chemotherapy with interferon for advanced-stage classical Hodgkin's lymphoma: A 10-year follow-up study. 2010 ASCO Annual Meeting Abstracts, 2010. e-Pub 2010.
41. Pro B, Perini GF, l F, Romaguera JE, Rodriguez MA, McLaughlin P, Hagemeister FB, Fayad L, Kadia T. Clinical features and treatment outcomes of angioimmunoblastic t-cell lymphoma. 2010 ASCO Meeting Abstracts, 2010. e-Pub 2010.
42. Pozazides JV, Perini G, Hess M, Romaguera JE, Hagemeister FB, McLaughlin P, Fayad L, Khouri IF, Hosing C, Pro B. Prognosis and treatment of patients with peripheral t-cell lymphoma: The MD Anderson Cancer Center experience. ASCO 2010 Annual Meeting Abstracts, 2010. e-Pub 2010.
43. Vadhan-Raj S, Fayad L, Fanale M, Pro B, Rodriguez A, Hagemeister F, Ames K, Bueso-Ramos C, Zhou X, McLaughlin P, Fowler N, Shah N, Samaniego F, Younes A, Kwak L, Romaguera J. Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome. Journal of the American Society of Hematology 114(22):48, 2009. e-Pub 2009.
44. Younes A, Gordon L, Kim S, Romaguera J, Copeland A, de Castro Farial S, Kwak L, Fayad L, Hagemeister F, Fanale M, Lambert J, Bagulho T, Morariu-Zamfir R. Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (NHL). Journal of the American Society of Hematology 114(22):243, 2009. e-Pub 2009.
45. Copeland A, Cao Y, Fanale M, Fayad L, McLaughlin P, Pro B, Hagemeister F, Romaguera J, Samaniego F, Rodriguez A, Younes A. Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Results of Long Follow up and Comparison to Institutional Historical Data. Journal of the American Society of Hematology 114(22):670, 2009. e-Pub 2009.
46. Fowler N, McLaughlin P, Hagemeister F, Kwak L, Fanale M, Neelapu S, Fayad L, Pro B, Sergent C, White S, Samaniego F. A Biologic Combination of Lenalidomide and Rituximab for Front-line Therapy of Indolent B-cell Non-Hodgkin's Lymphoma. Journal of the American Society of Hematology 114(22):683, 2009. e-Pub 2009.
47. Vadhan-Raj S, Fayad L, Fanale M, Pro B, Rodriguez A, Hagemeister F, Ames K, Bueso-Ramos C, Zhou X, McLaughlin P, Fowler N, Shah J, Samaniego F, Younes A, Kwak L, Romaguera J. Randomized clinical trial of rasburicase administered as a standard fixed five days dosing vs a single dose followed by as needed dosing in adult patients with hematologic malignancies at risk for developing tumor lysis syndrome. Blood (ASH Annual Meeting Abstracts) 114, 2009. e-Pub 2009.
48. Younes A, Gordon L, Kim S, Romaguera J, Copeland A, de Castro F, Kwak L, Fayad L, Hagemeister F, Fanale M, Lambert J, Bagulho T, Morariu-Zamfir R. Phase I multi-dose escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous (IV) infusion every 3 weeks to patients with relapsed/refractory b-cell non-Hodgkin's lymphoma (NHL). Blood (ASH Annual Meeting Abstracts) 114, 2009. e-Pub 2009.
49. Fowler N, McLaughlin P, Hagemeister F, Kwak L, Fanale M, Neelapu S, Fayad L, Pro B, Sergent C, White S, Samaniego F. A biologic combination of lenalidomide and rituximab for front-line therapy of indolent B-cell non-Hodgkin's lymphoma. Blood (ASH Annual Meeting Abstracts) 114, 2009. e-Pub 2009.
50. Wang L, Fayad L, Hagemeister F, Neelapu S, Samaniego F, McLaughlin P, Samuels B, Yi Q, Pro B, Fanale M, Shah J, Younes A, Bell N, Knight R, Zeldis J, Cabanillas F, Kwak L, Romaguera J. A phase I/II study of lenalidomide in combination with rituximab in relapsed/refractory mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts) 114, 2009. e-Pub 2009.
51. Westin J, Thompson M, Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemeister F. Bone loss in lymphoma patients receiving frontline therapy: Urine Ntx and bone specific alkaline phosphatase provide early evidence of zoledronic acid response. Blood (ASH Annual Meeting Abstracts) 114, 2009. e-Pub 2009.
52. Jones D, Windham J, Stewart B, Fayad L, Rodriguez A, Hagemeister F. Differential JAK-STAT Pathway Activation in primary mediastinal large b-cell lymphoma: Two subgroups with differential cytokine activation patterns and predicted responses to kinase inhibitors. Blood (ASH Annual Meeting Abstracts) 114, 2009. e-Pub 2009.
53. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophoshamide, and rituximab. Blood 111(12):5530-6, 2008. e-Pub 2008.
54. Rodriguez M, Fanale M, Hagemeister F, McLaughlin P, Pro B, Romaguera J, Kwak L, Fayad L, Durand AJ. Activity and toxicity of pegylated liposomal doxorubicin in combination regimen (DRCOP) for patients >60 years old with untreated diffuse large B cell lymphoma (DLBCL): A phase II study. Journal of Cinical Oncology 26(15s):725s, 2008. e-Pub 2008.
55. Shah N, Cabanillas F, Feng L, McIntyre B, McLaughlin P, Rodriguez MA, Romaguera J, Younes A, Hagemeister F, Kwak L, E Fayad AL. Prognostic value of serum CD44, ICAM-1 and VCAM-1 levels in patients with indolent non-Hodgkin's lymphomas. Journal of Clinical Oncology 26(15s):475s, 2008. e-Pub 2008.
56. Zhou X, Huen A, Teegala S, Ji Y, Fayad L, Hagemeister F, Vadhan-Raj AS. Incidence and significant predicting factors for chemotherapy-induced severe thrombocytopenia in lymphoma patients. Journal of Clinical Oncology 26(15s):726s, 2008. e-Pub 2008.
57. Suh GK, McLaughlin P, Romaguera J, Hagemeister F, Pro B, Khouri I, Samaniego F, Rodriguez M, Fayad L, Feng L, Younes AA. Long-term follow-up of paclitaxel and toptecan plus rituximab (TTR) for patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. Journal of Oncology 26(15s):478s, 2008. e-Pub 2008.
58. Cultera J, Nunez R, Romaguera J, Hagemeister F, Rodriguez M, Fayad L, Pro AB. Early (18F) flouro-2-deoxy-D-glucose positron emission tomography/computerized tomography (PET/CT) imaging as a tool for response assessment in T-cell non-Hodgkin's lymphoma (TCL): An update to a phase II study of HCVIDD alternated with methotrexate (MTX) and cytarabine (Ara-C). Journal of Clinical Oncology 26(15s):463s, 2008. e-Pub 2008.
59. Wedgwood AR, Fanale MA, Fayad LE, McLaughlin P, Hagemeister FB, Pro B, Romaguera J, Rodriguez MA, Samaniego F, Younes A. Rituximab + ABVD Improves Event-Free Survival (EFS) in Patients with Classical Hodgkin Lymphoma in All International Prognostic Score (IPS) Groups and in Patients Who Have PET Positive Disease after 2-3 Cycles of Therapy. Blood 110:71a, 2007. e-Pub 2007.
60. Zhou X, Huen A, Teegala S, Ji Y, Fayad L, Hagemeister FB, Vadhan-Raj S. Higher Incidence of Venous Thromboembolism Is Associated with Initial Cycles of Chemotherapy in Lymphoma Patients: Creatinine and Hemoglobin as Key Risk Factors 110:66B, 2007. e-Pub 2007.
61. Rodriguez MA, Fanale M, Hagemeister F, McLaughlin P, Pro B, Romaguera J, Kwak L, Fayad L, Huang X, Durand JB. Phase II Study of RCHOP with Pegylated Liposomal Doxorubicin (DRCOP) for Patients > 60 Years Old with Untreated Diffuse Large B Cell Lymphoma (DLBCL). Blood 110:187B, 2007. e-Pub 2007.
62. Fayad L, Pro B, Hagemeister F, Cabanillas F, Samaniego F, McLaughlin P, Wang M, Neelapu S, Kwak L, Romaguera J, Rodriguez MA. R-HCVAD/R-MTX-ARAC Is an Effective Regimen for Untreated Diffuse Large B-Cell Lymphoma (DLBCL) with Aggressive Features in Patients Younger Than 60 Years. Blood 110:387a, 2007. e-Pub 2007.
63. Tam CS, Ledesma C, Korbling M, Fayad LE, Wang M, Alousi A, Hosing C, Kebriaei P, Rondon G, Giralt SA, Anderlini P, Popat U, Couriel D, Pro B, Samuels B, Hagemeister F, Champlin RE, Khouri IF. Non-Myeloablative Allogeneic Stem Cell Transplantation (NMT) Overcomes the Adverse Effects of Treatment Resistance and High Beta-2-Microglobulin in Patients with Mantle Cell Lymphoma (MCL): An Analysis of 123 Transplantations at the MD Anderson Cancer Center. Blood 110:149a, 2007. e-Pub 2007.
64. Wang M, Fayad L, Hagemeister F, Neelapu S, Samuels B, Samaniego F, Pro B, Yi Q, Bell N, Byrne C, Weaver P, Hartig K, Knight R, Zeldis J, Kwak L, Romaguera J. Lenalidomide (Len) in Combination with Rituximab (R) Demonstrated Early Evidence of Efficacy in a Phase I/II Study in Relapsed/Refractory Mantle Cell Lymphoma (MCL). Blood 110:755a, 2007. e-Pub 2007.
65. Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, Cabanillas F, Rodriguez MA. The Addition of Rituximab to CHOP Chemotherapy Improves Response Rate, Failure-Free Survival and Overall Survival for Follicular Grade 3 Lymphoma Compared to CHOP Alone. Blood 110:388a, 2007. e-Pub 2007.
66. Pro B, Fayad L, Romaguera J, Fanale M, Younes A, Hagemeister FB, Samaniego F, McLaughlin P, Rodriguez MA, Kwak L, Dang NH. Preliminary Results of a Phase II Study of HCVIDDoxil Alternated with Methotrexate-Cytarabine in Patients with Newly Diagnosed T-Cell Lymphoma. Blood 110:1013A, 2007. e-Pub 2007.
67. Alousi AM, Hosing C, Saliba RM, Valverde RB, Maadani F, Korbling M, Okoroji GJ, Fayad LE, Stachowiak AM, Erwin WD, Anderlini P, de Lima MJ, Giralt SA, Popat UR, Kebriaei P, Ueno NT, McLaughlin PW, Pro B, Wang M, Rodriguez A, Hagemeister FB, Macapinlac HA, Podoloff DA, Champlin RE, Khouri IF. Zevalin/BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status. Blood 110:191a, 2007. e-Pub 2007.
68. Khouri IF, Saliba RM, Korbling M, Hosing C, Fayad L, Lee MS, Samaniego F, Samuels BI, Couriel D, Hagemeister F, McLaughlin P, Champlin RE. Nonmyeloablative Allogeneic Transplantation (NMT) for Relapsed Follicular Lymphoma (FL): Continuous complete Remission with Longer Follow-Up. Blood 110:150a, 2007. e-Pub 2007.
69. Teegala S, Zhou X, Huen A, Ji Y, Fayad L, Romaguera JE, Hagemeister FB, Vadhan-Raj S. High Incidence of Venous Thromboembolism in Patients with Lymphoma Receiving Chemotherapy: Assessment of Risk Factors. Blood 108, 2006. e-Pub 2006.
70. Huen A, Zhou X, Teegala S, Ji Y, Fayad L, Romaguera JE, Hagemeister FB, Vadhan-Raj S. Incidence and Risk Factors for Severe Thrombocytopenia in Lymphoma Patients Receiving Chemotherapy. Blood 108, 2006. e-Pub 2006.
71. Fayad L, Overman M, Pro B, McLaughlin P, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, Rodriguez MA. Favorable Results of Rituximab in Combination with CHOP in the Front-Line Treatment of Follicular Lymphoma Grade 3. Blood 108, 2006. e-Pub 2006.
72. Romaguera JE, Fayad L, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang L, Kantarjian HM, Beasley V, Medeiros LJ, Katz RL, Cabanillas F. Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A). Blood, 2006. e-Pub 2006.
73. Younes A, Fayad L, Goy A, McLaughlin P, Pro B, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Kwak L, Neelapu S, Medeiros LJ, Wedgwood A, Fanale M. Results of Rituximab Plus ABVD in 65 Newly Diagnosed Patients with Classical Hodgkin Lymphoma: Improvement of Event Free Survival (EFS) in All International Prognostic Score (IPS) Groups. Blood 108, 2006. e-Pub 2006.
74. Wang M, Oki Y, Pro B, Romaguera J, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister FB, Neelapu S, Podoloff D, Samuels B, Loyer E, Zhou Y, Younes A. Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL). Blood 108, 2006. e-Pub 2006.
75. Falchook GS, Champlin R, Hagemeister FB, Hosing C, Kwak LW, O’Brien S, Rodriguez MA, Verstovsek S, Pro B. Hepatosplenic T-Cell Lymphoma: Clinical Characteristics and Treatment Outcome. Blood 108, 2006. e-Pub 2006.
76. Pro B, Nunez RF, Romaguera J, Rodriguez MA, Hagemeister FB, Fayad L. Achievement of FDG-PET Negativity Does Not Predict Durable Responses in T-Cell Lymphoma. Blood 108, 2006. e-Pub 2006.
77. Khouri IF, Saliba RM, Hosing C, Valverde R, Erwin WD, Fayad L, Maadani F, Korbling MJ, Okoroji GJ, Stachowiak AM, Samuels BI, Anderlini P, Couriel DR, de Lima M, Geralt S, Popat U, Kebriaci P, Ueno NT, Qazilbash MH, McLaughlin PW, Hagemeister FB, Younes A, Podoloff DA, Champlin RE. Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin’s Lymphoma (NHL). Blood 108, 2006. e-Pub 2006.
78. Safdar, Amar, Rodriguez, Alma M, Fayad, Luis E, Rodriguez, Gilhen H, Pro, Barbara, Wang, Michael, Romaguera, Jorge E, Goy, Andre H, Hagemeister, Fredrick B, McLaughlin, Peter, Bodey, Gerald P, Kwak, Larry W, Raad, Issam I, Couch, Robert B. Dose-Related Safety and Immunogenicity of Baculovirus-Expressed Trivalent Influenza Vaccine: A Double-Blind, Controlled Trial in Adult Patients with Non-Hodgkin B Cell Lymphoma. Journal of Infectious Diseases 194(10):1394-1397, 2006. e-Pub 2006.
79. Thompson MA, Pro B, Sarris A, Hagemeister FB, Goy A, Bleyer A, Cabanillas FF, Samaniego F, Fayad LE. Results of a Phase II Study of 506U78 (Nelarabine) in Refractory Indolent B-Cell or Peripheral T-Cell Lymphoma. Blood(Part I):753A, 2005. e-Pub 2005.
80. Fayad L, Romaguera J, Hart S, Younes A, Pro B, Hagemeister FB, McLaughlin P, Dang N, Pretti A, Sarris A, Gil F. Report of a Phase II Study of Sphingosomal Vincristine (SV) in Patients with Relapsed or Refractory Hodgkin’s Disease. J Clin Oncol 23, 2005. e-Pub 2005.
81. Pro B, Smith MR, Leber B, Younes A, Fayad L, Hagemeister FB, McLaughlin P, Rodriguez MA, Caddick Y, Zwiebel JA. Phase II Study of Oblimersen Sodium and Rituximab in Patients with Recurrent B-Cell Non-Hodgkin’s Lymphoma. J Clin Oncol 23, 2005. e-Pub 2005.
82. Oki Y, Pro B, Delpassand E, Ballaster V, McLaughlin P, Romaguera J, Wang M, Hagemeister FB, Younes A. A Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Treatment of Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL). Blood 104, 2004. e-Pub 2004.
83. Rodriguez, MA, Dang NH, Fayad L, Goy A, Hagemeister FB, McLaughlin P, Pro B, Romaguera JE, Younes A, Cabanillas F. Sphingosomal Vincristine in CHOP Is A Promising New Treatment For Elderly, As Well As Poor Prognosis Patients With Aggressive Non-Hodgkin’s Lymphoma (NHL): Follow-Up Results Of A Phase II Study. 2004 Annual Meeting of the American Society of Clinical Oncology, 2004. e-Pub 2004.
84. Dang, NH, Pro B, Hagemeister FB, Jones D, Samuels B, Rodriguez MA, Goy A, Romaguera JE, Walker PL, Kwak L, Fayad L. Interim Analysis of a Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin’s Lymphoma. Blood 104, 2004. e-Pub 2004.
85. Yee, KWL, Wierda W, O’Brien SO, Thomas D, Kurzrock R, Fayad LE, Hagemeister FB, Cortes J, Prestifilippo J, Szatrowski TP, Kantarjian HM, Giles FJ. A Phase I/II Study of the Oral mTOR Inhibitor RAD001 in Patients with Advanced Hematologic Malignancies. Blood 104, 2004. e-Pub 2004.
86. Rodriguez, MA, Sarris A, Dang NH, Fayad L, Goy A, Hagemeister F, McLaughlin P, Pro B, Romaguera J, Samaniego F, Younes A, Cabanillas F. Sphingosomal Vincristine in CHOP +/- Rituximab Is a Promising New Treatment for Patients with High Risk Untreated Aggressive Non-Hodgkin’s Lymphoma (NHL): Follow-Up Results of a Phase II Study. Blood 104, 2004. e-Pub 2004.
87. Oki, Y, McLaughlin P, Pro B, Hagemeister FB, Bleyer A, Loyer E, Younes A. Phase II Study of Oxaliplatin in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma: Final Results. Blood 104, 2004. e-Pub 2004.
88. Romaguera, JE, Fayad L, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Medeiros LJ, Katz R, Gagneja H, Samuels BI, Cabanillas F. Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-Dose Methotrexate-Cytarabine (R-M/A) in Untreated Mantle Cell Lymphoma (MCL): Prolonged Follow-Up Confirms High Rates of Failure-Free Survival (FFS) and Overall Survival (OS). Blood 104, 2004. e-Pub 2004.
89. Goy, A, Younes A, McLaughlin P, Pro B, Romaguera J, Hagemeister F, Fayad L, Trehu EG, Schenkein D, Rodriguez MA. Update on a Phase (ph) 2 Study of Bortezomib in Patients (pts) With Relapsed or Refractory Indolent or Aggressive Non-Hodgkin’s Lymphoma (NHL). Annual Meeting of the American Society of Clinical Oncology:Abstract 6581, 2004. e-Pub 2004.
90. McLaughlin, P, Estey E, Glassman A, Romaguera J, Samaniego F, Ayala A, Hayes K, Maddox AM, Preti A, Hagemeister FB. Myelodysplasia and Acute Myeloid Leukemia Following Therapy for Indolent Lymphoma with Fludarabine, Mitoxantrone, Dexamethasone (FND) Plus Rituximab and Interferon Alfa. Blood 104:Abstract 1394, 2004. e-Pub 2004.
91. Pro, B, Smith MR, Younes A, Fayad LE, Goy AH, Hagemeister FB, McLaughlin P, Rodriguez MA, Frankel SR, Zwiebel JA. Oblimersen Sodium (Bcl-2 antisense) Plus Rituximab in Patients With Recurrent B-Cell Non-Hodgkin’s Lymphoma: Preliminary Phase II Results. 2004 Annual Meeting of the American Society of Clinical Oncology:Abstract 6572, 2004. e-Pub 2004.
92. Sarma, A, Rodriguez MA, Cabanillas F, Dang NH, McLaughlin P, Hagemeister FB, Pro B, Romaguera J, Younes A, Grimm EA. A Randomized Trial of CHOP Chemotherapy With or Without Melatonin in Patients With Favorable Prognosis Large B-Cell Lymphoma. 2004 Annual Meeting of the American Society of Clinical Oncology, 2004. e-Pub 2004.
93. Younes, A, McLaughlin P, Pro B, Hagemeister F, Bleyer A. Phase II study of Oxaliplatin in patients with relapsed and refractory non-Hodgkin lymphoma. Blood 102:11, 2003. e-Pub 2003.
94. Goy, A, Bleyer A, Hagemeister F, Fayad L, Pro B, Romaguera J, Samaniego F, Sarris A, Hart S, Cabanillas F, Murgo A, Duvic M, Rodriguez M. Phase II study of compound GW506U78 (AraG) for patients with indolent B-cdll or peripheral T-cell lymphoma previously treated with chemotherapy. Blood 102:11, 2003. e-Pub 2003.
95. Goy, A, Hart S, Pro B, McLaughlin P, Younes A, Dang N, Fayad L, Romaguera J, Cabanillas F, Hagemeister F, Samaniego F, Wang M, Mesina O, Gilles F, Trehu E, Shenkein D. Report of a phase II study of Proteasome inhibitor Borezomib (VELCADE™) in patients with relapsed or refractory indolent or aggressive lymphomas. Blood 102:11, 2003. e-Pub 2003.
96. Younes, A, McLaughlin P, Romaguera J, Hagemeister F, Pro B, Dang N, Samaniego F, Rodriguez M, Fayad L. Taxol plus Topotecan plus Rituximab (TTR) with G-CSF support: An effective salvage program for the treatment of patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL) who failed CHOP-like and platinum-based therapy. Blood 102:11, 2003. e-Pub 2003.
97. Younes, A, Fayad L, Pro B, McLaughlin P, Hagemeister F, Mansfield P, Clayman G, Medeiros L, Manning J, Lewis J, Srivastava P. Safety and efficacy of heat shock protein-peptide 96 complex (HSPPC-96) vaccine therapy in patients with relapsed or previously untreated low-grade non-Hodgkin lymphoma. Blood 102:11, 2003. e-Pub 2003.
98. Liu, N, Grimm EPoindexter N, Rodriguez M, Hagemeister F, Pro B, Fayad L, Lee B, Reuben J, McLaughlin P. Antibody dependent cellular cytotoxicity and natural killer cell activitiy in patients with recurrent indolent lymphoma receiving rituximab in combination with GM-CSF. Blood 102:11, 2003. e-Pub 2003.
99. Liu, Q, Fayad L, Hagemeister F, Rodriguez M, Younes A, Pro B, Verstovsek S, Cabanillas F, Tsimberidou A, Hess M, Ayala A, Clemons M, McLaughlin P. Stage IV indolent lymphoma: 25 years of treatment progress. Blood 102:11, 2003. e-Pub 2003.
100. Dang, N, Hagemeister F, Fayad L, Pro B, McLaughlin P, Romaguera J, Samaniego F, Goy A, Wang M, Walker P, Samuels B, Jones D, Rodriguez M. Analysis of a phase Ii study of Denileukin Diftitox (ONTAK®) for B and T-cell non-Hodgkin’s lymphoma. Blood 102:11, 2003. e-Pub 2003.
101. Pro, B, Smith M, Younes A, Dang N, Fayad L, Goy A, Hagemeister F, McLaughlin P, Rodriguez M, Samuels B, Arredondo Y, Frankel S, Zwiebel J. Genasense (Bcl-2 Antisense) plus Rituximab is active in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. Blood 102:11, 2003. e-Pub 2003.
102. Pro, B, Cabanillas F, Dang N, Fayad L, Goy A, McLaughlin P, Rodriguez M, Romaguera J, Samaniego F, Hi W, Hess M, Gold D, Hagemeister F. Prognostic factors in follicular lymphoma: The importance of Beta-2 Microglobulin. Blood 102:11, 2003. e-Pub 2003.
103. Rodriguez, M, Van Vesien K, Hagemeister F, Giralt S, McLaughlin P, Gajewski J, Romaguera J, Khouri I, Younes A, Cabanillas F, Champlin R. Randomized comparison of Frontline Alternating Chemotherapy (ATT) versus brief induction followed by autologous stem cell transplant (ASCT) for aggressive lymphomas. Blood 102:11, 2003. e-Pub 2003.
104. Younes, A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, Goy A, Jeha S, Manning J, Mediros J, Cabanillas F. Evaluation of rituximab in the treatment of patients with relapsed classical Hodgkin’s Disease (HD): Single agent and combination studies. Ann Oncol 13:64, 2002. e-Pub 2002.
105. Younes, A, Robertson MJ, Flinn IW, Romaguera J, Hagemeister FB, Cabanillas F, Rodriguez MA, Dang N, Samaniego F. A Phase II Study of Interleukin-12 (IL-12) in Patients with Relapsed Non-Hodgkin Lymphoma and Hodgkin’s Disease. ASH/Blood 100:364a, 2002. e-Pub 2002.
106. Younes, A, Barbara P, Rodriguez MA, Romaguera J, Hagemeister FB, Cabanillas F. Preliminary results on efficacy of single administration of a fixed dose of pegfilgrastim (pegylated filgrastim) in inducing neutrophil count recovery after paclitaxel plus topotecan chemotherapy in patients with relapsed lymphoma. Ann Oncol 13:174, 2002. e-Pub 2002.
107. Younes, A, Pro B, Rodriguez MA, Romaguera J, Hagemeister F, Cabanillas F. Efficacy of single administration of a fixed dose pegfilgrastim (pegylated G-CSF) in inducing neutrophil count recovery after Taxol plus Topotecan chemotherapy in patients with relapsed lymphoma. Ann Oncol 13:169, 2002. e-Pub 2002.
108. Younes, A, McLaughlin P, Hagemeister FB, Pro B, Samaniego F, Romaguera JE, Dang NH, Fayad L, Goy A, Rodriguez MA, Cabanillas F. Addition of Rituximab to Taxol plus Topotecan (TTR) improves response rate and complete remission rate in patients with relapsed/refractory aggressive B-cell lymphoma. Ann Oncol 13:74, 2002. e-Pub 2002.
109. Younes, A, Fayad L, McLaughlin P, Goy AH, Romaguera J, Rodriguez MA, Hagemeister FB, Samaniego F, Pro B, Medeiros LJ, Ha C, Wilder R, Seifert A. Rituximab Plus ABVD Therapy for Newly Diagnosed Patients with Classical Hodgkin’s Disease. ASH/Blood 100:308B, 2002. e-Pub 2002.
110. Younes, A, McLaughlin P, Pro B, Hagemeister FB, Fayad L, Romaguera J. Activity of Oxaliplatin in Patients with Relapsed and Refractory Non-Hodgkin’s Lymphoma. ASH/Blood 100:296b, 2002. e-Pub 2002.
111. Younes, A, Pro B, Hagemeister FB, Rodriguez MA, McLaughlin P, Fayad L, Goy A, Cabanillas F. Efficacy of Single Administration of a Fixed Dose Pegfilgrastim (Neulasta) in Inducing Neutrophil Count Recovery after Paclitaxel Plus Topotecan Chemotherapy in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma. ASH/Blood 100:727a, 2002. e-Pub 2002.
112. Hu, G, Rodriguez MA, Romaguera J, McLaughlin P, Younes A, Cox J, Medeiros J, Samuels B, Cabanillas F, Hagemeister F. Pregnancy (PG) in the patient with lymphoma does not predict an adverse prognosis. Proc ASCO/JCO 21:286a, 2002. e-Pub 2002.
113. Goy, A, Sarris AH, Bleyer A, Duvic M, Mesina O, Dang NH, Fayad L, Hagemeister F, McLaughlin P, Pro B, Rodriguez MA, Romaguera J, Samaniego F, Younes A, Cabanillas F. Phase II Study of Compound GW506U78 (AraG) in Patients with T-Cell and B-Cell Non-Hodgkin’s Lymphomas (NHL). ASH/Blood 100:304B, 2002. e-Pub 2002.
114. Sarris, AH, Rodriguez MA, Mesina O, King K, Phan A, Hagemeister FB, Romaguera J, McLaughlin P, Pro B, Dang N, Medeiros LJ, Samuels B, Burge C, Saltman D, Cabanillas F. Liposomal vincristine in relapsed or refractory non-Hodgkin’s lymphomas: Final results of a phase II trial. Ann Oncol 13:168, 2002. e-Pub 2002.
115. Romaguera, JE, Hagemeister FB, Fayad LE, Rodriguez MA, Medeiros LJ, Pro B, Younes A, Sarris AH, Dang NH, Samaniego F, Brown HM, Gagneja HK, Cabanillas F. The Clinical Significance of Detection of Gastrointestinal (GI) Involvement in Mantle Cell Lymphoma (MCL). ASH/Blood 100:281b, 2002. e-Pub 2002.
116. Romaguera, J, Cabanillas F, Dang N, Goy A, Fayad L, Hagemeister FB, McLaughlin P, Pro B, Rodriguez MA, Samaniego F, Sarris A, Younes A, Medeiros J, Gagneja GH. Mantle cell lymphoma (MCL)-Update on results after R-HCVAD without stem cell transplant (SCT). Ann Oncol 13:8, 2002. e-Pub 2002.
117. Rodriguez, MA, Sarris A, East K, Dang NH, Fayad L, Goy A, Hagemeister FB, McLaughlin P, Pro B, Romaguera J, Samaniego F, Younes A, Cabanillas F. A Phase II Study of Liposomal Vincristine in CHOP with Rituximab for Patients with Untreated Aggressive B-cell Non-Hodgkin’s Lymphoma (NHL): A Safe and Effective Combination. ASH/Blood 100:92a, 2002. e-Pub 2002.
118. Rodriguez, MA, Sarris A, East K, Dang NH, Fayad L, Goy A, Hagemeister F, Pro B, Romaguera J, Samaniego F, Younes A, Cabanillas F. A phase II study of liposomal vincristine in CHOP with rituximab for elderly patients with untreated aggressive B-cell non-Hodgkin’s lymphoma. Proc ASCO/JCO 21:284a, 2002. e-Pub 2002.
119. Dang, NH, Hagemeister FB, Fayad L, Pro B, McLaughlin P, Romaguera JE, Samaniego F, Younes A, East K, Rodriguez MA, Cabanillas F. Phase II Study of Dilineukin Difititiox (ONTAKÒ) for Relapsed/Refractory B and T-Cell Non-Hodgkin’s Lymphoma. ASH/Blood 100:363a, 2002. e-Pub 2002.
120. Pro, B, Romaguera J, Macapinlac HA, Fayad L, Dang NH, Samaniego F, Goy A, Rodriguez MA, McLaughlin P, Podoloff DA, Hagemeister F, Younes A, Cabanillas F. Positron Emission Tomography Using Fluorodeoxyglucose but not Gallium-67 Scintigraphy Is a Sensitive Imaging Modality in the staging of Mantle Cell Lymphoma. ASH/Blood 100:769a, 2002. e-Pub 2002.
121. King, KM, Wood AM, Arbuckle RB, Adamus AT, Hagemeister FB. Collection of infectious disease and economic outcomes for non-Hodgkin’s lymphoma and multiple myeloma patients admitted for infectious complications utilizing a palm handheld. J Intl Soc Pharcoeco Outcome Res 5:194, 2002. e-Pub 2002.
122. King, KM, Wood AM, Arbuckle RB, Adamus AT, Hagemeister FB. Collection of infectious disease and economic outcomes for non-Hodgkin’s lymphoma and multiple myeloma patients admitted for infectious complications utilizing a Palm handheld. Proc ASCO/JCO 21:197b, 2002. e-Pub 2002.
123. Wu, HH, Hagemeister FB, Hess M, Smith TL, McLaughlin P, Romaguera J, Rodriguea MA, Younes A, Manning J, Cox J, Muller M, Cabanillas F. Relapse (Rel) and Transformation (TF) of follicular lymphoma: Prognostic factors and effect on survival. Ann Oncol 13:55, 2002. e-Pub 2002.
124. Tsimberidou, A-M, McLaughin P, Feng L, Ayala A, Younes A, Rodriguez MA, Romaguera J, Hagemeister FB, Smith TL, Cabanillas F. Duration of Decreased Absolute Number of Circulating CD4 Cells and CD4/CD8 Ratio in Patients with Indolent Lymphoma Treated with Fludarabine. ASH/Blood 100:775a, 2002. e-Pub 2002.
125. Wu, HH, Hagemeister FB, Hess MA, McLaughlin PW, Romaguera JE, Rodriguez MA, Younes A, Manning JT, Cox JD, Muller M, Cabanillas FF. Transformation of follicular lymphoma: Prognostic factors and effect on survival. Proc ASCO/JCO 21:283a, 2002. e-Pub 2002.
126. Anderlini, P, Acholonu S, Giralt S, Ueno N, Andersson B, Khouri I, Romaguera J, Rodriguez M, Hagemeister F, Cabanillas F, Champlin R. Allogeneic stem cell transplantation (SCT) with fludarabine-based, less intensive conditioning in high-risk, relapsed/resistant Hodgkin’s disease (HD). Ann Oncol 13:121, 2002. e-Pub 2002.
127. Hagemeister FB. Rituximab Plus Hyper-CVAD for Mantle Cell Lymphoma. Updated Results. . Biol Ther of Lymph 5(5):3-6, 2002. e-Pub 2002.
128. Hagemeister FB. Review of a Randomized Controlled Trial of Yttruim-90-Labeled Ibritumomab Tiuxetan Radioimmunotherapy versus Rituximab Immunotherapy for Patients with Relapsed or Refractory Low-Grade, Follicular, or Transformed B-cell Non-Hodgkin’s lymphoma. Am J Oncol Rev 1(4):222-224, 2002. e-Pub 2002.
129. Hagemeister, FB, McLaughlin P, Clemons M, Rodriguez MA, Fayad L, Romaguera J, Pro B, Goy A, Samaniego F, Dang NH, Cabanillas F. FND (Fludarabine, Mitoxantrone, Dexamethasone)-R (Rituximab) for Patients (pt) with Relapsed (Rel) or Chemotherapy Resistant (CTR) Indolent Lymphomas (IL): A Preliminary Report. ASH/Blood 100:305b, 2002. e-Pub 2002.
130. Younes, A, McLaughlin P, Hagemeister FB, Pro B, Samaniego F, Romaguera JE, Dang NH, Fayad L, Goy A, Rodriguez MA, Cabanillas F. High response rate and complete remission rate achieved by adding Rituximab to Taxol plus Topotecan (TTR) with G-CSF support for the treatment of patients with relapsed/refractory aggressive B-cell lymphoma. Blood 98:345a, 2001. e-Pub 2001.
131. Younes, A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, Goy A, Jeha S, Manning J, Medeiros LJ, Martinez RF, Cabanillas F. Depletion of Normal B-Lymphocytes by Rituximab Therapy Alters Serum Cytokine Levels, Resolves B-symptoms and Induces Clinical Remissions in Patients with Relapsed classical Hodgkin’s Disease (HD). Blood 98:132a, 2001. e-Pub 2001.
132. Younes, A, Hagemeister F, Romaguera J, Dang N, Fiumara P, McLaughlin P, Rodriguez MA, Samaniego F, Khouri I, Cabanillas F. Interleukin-12 (IL-12) decreases serum VEGF and b-FCG levels and induces clinical remissions in patients with relapsing non-Hodgkin’s lymphoma (NHL). ASH/Blood 98:612a, 2001. e-Pub 2001.
133. Barista, I, Hagemeister FB, Podoloff DA, Rodriguez MA, McLaughlin P, Romaguera JE, Ha CS, Wilder RB, Younes A, Sarris A, Cabanillas F. “The positive (POS) Gallium Scan (GA-67) in Hodgkin’s Disease (HD) at Endo of Therapy Predicts Freedom from Progression (FFP) and Overall Survival (OS) Results. ASH/Blood 98:126a, 2001. e-Pub 2001.
134. Khouri, IF, Saliba RM, M-S L, Giralt S, Younes A, Couriel D, Fayad L, deLima M, Hagemeister FB, Hosing C, McLaughlin P, Ueno N, Rodriguez MA, Korbling M, Gajewski J, Cabanillas F, Champlin RE. Nonablative allogeneic stem cell transplantation (AST) for non-Hodgkin’s lymphoma (NHL): Improved outcome with low incidence of acute GVHD and treatment related mortality. Blood 98:416a, 2001. e-Pub 2001.
135. Khouri, IF, Saliba RM, Younes A, Acholonu S, Andersson B, Bibawi S, deLima M, Fayad L, Giralt S, Hagemeister FB, Korbling M, Rodriguez MA, Romaguera J, Cabnaillas F, Champlin RE. Allogeneic transplantation for poor risk mantle cell lymphoma (MCL): Chemosensitivity predicts superior outcome. Blood 98:416a, 2001. e-Pub 2001.
136. Khouri, I, Saliba RM, Giralt SA, M-S L, G-J O, Hagemeister FB, Korbling M, Younes A, Ippoliti C, Gajewski JL, McLaughlin P, Anderlini P, Donato ML, Cabanillas F, Champlin RE. Prolonged failure free survival and molecular responses with nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma. Blood 98:744a, 2001. e-Pub 2001.
137. Sarris, AH, Visco C, Medeiros LJ, Mesina O, Rassidakis GZ, Rodriguez MA, McLaughlin P, Goy A, Hagemeister FB, Romaguera JE, Samaniego F, Dang N, Pro B, Fayad L, Ha C, Wilder R, Cox J, Cabanillas F. Non-Hodgkin’s lymphoma involving the testis: Results of treatment with CHOP, Intrathecal methotrexate and scrotal radiotherapy. Blood 98:345a, 2001. e-Pub 2001.
138. Dang, NH, Hagemeister FB, Duvic M, Romaguera JE, Younes A, Rodriguez MA, Sarris AH, Jones D, East K, Gomez R, Fayad LE, Pro B, McLaughlin P, Samaniego F, Goy A, Cabanillas F. Phase II Study of Pentostatin for Relapsed T cell Lymphomas: Efficacy and Effect on CD26+ T cells. ASH/Blood 98:130a, 2001. e-Pub 2001.
139. Pro, B, Younes A, Albitar M, Hagemeister FB, Rodriguez MA, McLaughlinP, Clemons M, Samaniego F, Cabanillas F. Phase II study of Thalidomide in patients with recurrent Hodgkin’s Disease (HD) and non-Hodgkin’s lymphomas (NHL). Blood 98:247b, 2001. e-Pub 2001.
140. Rodriguez, MA, Dang NH, East K, Fayad L, Goy A, Hagemeister F, McLaughlin P, Pro B, Romaguera J, Samaniego F, Sarris A, Younes A, Cabanillas F. Melatonin did not prevent CHOP-induced myelosuppression in patients with aggressive lymphoma: Results of a randomized study. Blood 98:246b, 2001. e-Pub 2001.
141. Romaguera, J, Cabanillas F, Dang NH, Goy A, Hagemeister FB, Fayad L, McLaughlin P, Pro B, Rodriguez MA, Samaniego F, Sarris AH, Younes A, Medeiros J. Mantle cell lymphoma (MCL)-High rates of complete remission (CR) and prolonged failure-free survival (FFS) with Rituxan-HyperCVAD (R-HCVAD) without stem cell transplant (SCT). Blood 98:726a, 2001. e-Pub 2001.
142. McLaughlin, P, Rodriguez MA, Reuben J, East K, Grimm E, Hagemeister FB, Fayad L, Sarris A. Rituximab in combination with GM-CSF (Leukine) for Patients with recurrent indolent lymphoma. Blood 98:605a, 2001. e-Pub 2001.
143. Fayad, LE, Romaguera J, Pro B, Younes A, Dang NH, Samaniego F, Garcia-Tejido P, Sarris A, Rodriguez MA, Hagemeister F, McLaughlin P, Goy A, Cabanilla F, Rodriguez P. Primary Mediastinal Large B-cell Lymphoma (PMLBL): Poor Prognosis in Patients with Extranodal Sites. Blood 98:336a, 2001. e-Pub 2001.
144. Younes, A, Romaguera J, Hagemeister F, Rodriguez M, McLaughlin P, Medeiros J, Cabanillas F. A pilot study of rituximab in patients with relapsed Hodgkin’s disease of classical type. ASH/Blood:733a, 2000. e-Pub 2000.
145. Cabanillas, F, McLaughlin P, Hagemeister F, Rodriguez MA, Romaguera JE, Younes A, Sarris AH, Pro B, Dang N, Samaniego F, Lee MS. Molecular responses with FND + Rituxan chemoimmunotherapy for stage IV indolent follicular non-Hodgkin’s lymphoma. ASH/Blood 96:331a, 2000. e-Pub 2000.
146. Sarris, AH, Romaguera J, Hagemeister F, Rodriguez MA, McLaughlin P, Dang N, Tsimberidou AM, Medeiros LJ, Samuels B, Oholendt M, Mesina O, Burge, C, Cabanillas F. Liposomal Vincristine: A Phase II Trial In Relapsed or Refractory Non- Hodgkin’s Lymphoma (NHL). . 7th International Liposome Research Days, 2000. e-Pub 2000.
147. Sarris, AH, Hagemeister F, McLaughlin P, Rodriguez MA, Pro B, Romaguera J, Zipf T, Mesina O, Medeiros LJ, Oholendt M, Lopez-Berenstein G, Ford R, Williams T, Cabanillas F. Liposomal tretinoin: Promising early results of an ongoing phase II trial in relapsed or refractory non-Hodgkin’s lymphomas (NHL) and cutaneous T-cell lymphomas (CTCL). ASH/Blood 96:136a, 2000. e-Pub 2000.
148. Romaguera, J, Dang N, Hagemeister FB, McLaughlin P, Pro B, Rodriguez MA, Samaniego F, Sarris A, Younes A, Cabanillas F. Evidence for need of upper and lower endoscopies with biopsy in staging of asymptomatic patients with aggressive mantle cell lymphoma (MCL). ASH/Blood:334a, 2000. e-Pub 2000.
149. Sarris, AH, Medeiros LJ, Rassidakis G, Nadali G, Viviani S, Vassilakopoulos TP, Giardini R, Chilosi M, Kittas C, Angelopoulou M, Herling M, Hagemeister FB, Rodriguez MA, Romaguera J, McLaughlin P, Ford R, Gianni M, Bonodonna G, Pangalis GA, Pizzolo G, Cabanillas F. BCL-2 expression in Hodgkin-Reed-Sternberg cells (HRS) of patients (pts) with classical Hodgkin’s disease (CHD) is associated with lower progression-free survival (PFS) and survival. ASH/Blood:725a, 2000. e-Pub 2000.
150. Rodriguez, MA, Cabanillas F, Dang NH, Grimm EA, McLaughlin P, McAda N, Hagemeister FB, Romaguera J, Sarris A, Younes A, Richarson MA. Lymphocyte changes in lymphoma patients receiving melatonin plus CHOP cheomotherapy. Proc ASCO 19:20a, 2000. e-Pub 2000.
151. Romaguera, JE, Dang NH, Hagemeister FB, McLaughlin P, Pro B, Rodriguez MA, Samaniego F, Sarris A, Younes A, Medeiros J, Steinbach G, Cabanillas F. Preliminary report of rituximab with intensive chemotherapy for untreated aggressive mantle cell lymphoma (MCL). ASH/Blood:733a, 2000. e-Pub 2000.
152. Pro, B, Hagemeister FB, Rodriguez MA, Hess M, Romaguera J, McLaughlin P, Younes A, Sarris AH, Ha C, Cox J, Cabanillas F. Early stage Gastric Lymphoma: Excellent cure rates without surgery. Proc ASCO/JCO 20, 2000. e-Pub 2000.
153. Tsimberidou, AM, McLaughlin P, Younes A, Rodriguez MA, Hagemeister FB, Sarris A, Romaguera J, Preti A, M-S L, Cabanillas F. Randomized comparison of fludarabine-novantrone-dexamethasone (FND) versus CHOD-BLEO/ESHAP/NOPP (Alternating triple therapy; ATT) in patients with stage IV indolent lymphoma. ASH/Blood:508a, 2000. e-Pub 2000.
154. Seymour, JF, McLaughlin P, Fuller LM, Hagemeister FB, Hess M, Romaguera J, Rodriguez MA, Ha C, Cox J, Cabanillas F. Fifteen-year follow-up of a prospective MD Anderson study of combined-modality therapy for localized indolent non-Hodkgin’s lymphoma. ASH/Blood:509a, 2000. e-Pub 2000.
155. Anderlini, P, Giralt S, Ueno N, Andersson B, Khouri I, Acholonu S, Cohen A, Manning J, Korbling M, Romaguera J, Sarris A, Rodriguez M, Hagemeister F, McLaughlin P, Cabanillas F, R: C. Allogeneic stem cell transplantation (SCT) with Fludarabine-based, less intensive conditioning as adoptive immunotherapy in advanced Hodgkin’s disease (HD). Proc ASCO 19:62a, 2000. e-Pub 2000.
156. Nadali, G, Sarris AH, Viviani S, Bonfante V, Micheletti M, Notti P, Peethambaram P, Preti A, Hagemeister F, Romaguera J, McLaughlin P, Rodriguez MA, Tsimberidou AM, Chilosi M, Witzig T, Cabanillas F, Pizzolo G. sCD30, Progression-free survival (PFS), and survival (surv) in Hogkin's disease (HD) patients (PTS). Proc ASH/Blood 94:514a, 1999. e-Pub 1999.
157. Younes, A, Okpara N, Romaguera JE, Hagemeister FB, McLaughlin P, Rahman D, Cabanillas F. Phase II study of paclitaxel plus topotecan with G-CSF support for the treatment of relapsed and refractory aggressive non-Hodgkin's lymphoma. ASH/Blood 94:270b, 1999. e-Pub 1999.
158. Herling, M, Medeiros LJ, Kliche KO, Khorann S, Mesina O, Hagemeister FB, Romaguera J, McLaughlin P, Preti HA, Rodriguez MA, Cabanillas F, Sarris AH. Expression of the EBV-coded latent membrane protein-1 (LMP-1) in Hodgkin-Reed-Sternberg cells is associated with inferior progression-free survival in Hodgkin's disease (HD). Onkologie 22:Abstract 476a, 1999. e-Pub 1999.
159. Khouri, I, Romaguera J, Kantarjian H, Korblin M, Younes A, Giralt S, Hagemeister F, Gajewski J, Sarris A, Claxton D, McLaughlin P, Donato M, Rodriguez M, Ueno N, Champlin R, Cabanillas F. Update of the HCVAD regimen followed by stem cell transplantation (SCT) in mantle cell lymphoma (MCL). ASH/Blood 94:610a, 1999. e-Pub 1999.
160. Cabanillas, F, Lee MS, McLaughlin P, Cox J, Hagemeister FB, Ha C, Rodriguez MA, Romaguera J, Sarris A, Younes A. Detection of minimal residual disease by bcl-2 PCR in early stage follicular lymphomas. Oncology 13:25-26, 1999. e-Pub 1999.
161. Cabanillas, F, López-Guillermo A, McLaughlin P, Hagemeister F, Rodriguez MA, Romaguera JE, Younes A, Sarris AH, Preti HA, Lee MS. Clinical significance of a molecular relapse in patients with follicular lymphoma (FL) who achieve a molecular response. ASH/Blood 94:598a, 1999. e-Pub 1999.
162. Sarris, AH, Viviani S, Bonfante V, Nadali G, Kliche KO, Micheletti M, Notti P, Peethambaram P, Preti A, Hagemeister F, Romaguera J, McLaughlin P, Rodriguez MA, Chilosi M, Cox J, Witzig T, Gianni M, Bonadonna G, Pizzolo G, Cabanillas F. Serum IL-10 and progressio-free survival (PFS) in Hodgkin's disease (HD) patients (PTS) treated only with radiotherapy (RT). ASH/Blood 94:515a, 1999. e-Pub 1999.
163. Verstovsek, S, Romaguera JE, Cabanillas F, Hagemeister FB, Rodriguez MA, McLaughlin P. CHOP-BLEO plus interferon-a for stage IV low grade lymphoma-An update after 13-year follow up: Significant improvement in both overall and failure-free survival. ASH/Blood 94:270b, 1999. e-Pub 1999.
164. Lopez-Guillermo, A, Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Rodriguez MA, Romaguera J, Younes A, Sarris AH, Preti HA, Pugh W, Lee MS. Molecular response assessed by PCR is the most important factor predicting failure-free survival (FFS) in indolent follicular lymphoma (FL). Proc Internatl Conf Malig Lymphoma, 1999. e-Pub 1999.
165. Pro, B, Hagemeister FB, Rodriguez MA, Romaguera J, McLaughlin P, Cox J, Cabanillas F. Primary Large-Cell Lymphoma: M.D. Anderson Cancer Center 40-year experience. Proc Internatl Conf Malig Lymphoma, 1999. e-Pub 1999.
166. Rodriguez, J, Cabanillas F, McLaughlin P, Rodriguez M, Hagemeister FB, Romaguera J, Sarris AH, Younes A. Serum B-2 microglobulin improves the prognostic discriminatin of the International Prognostic Indes (IBP). Proc Internatl Conf Malig Lymphoma, 1999. e-Pub 1999.
167. Rodriguez, J, Khouri I, Palmer L, Rodriguez M, Giralt S, Hagemeister F, Korbling M, Younes A, McLaughlin P, Cabanillas F, Champlin. Salvage therapy with hematopoietic cell transplantation (HCT) in peripheral-T-cell lymphomas (PTCL). Proc ASH/Blood 94:172a, 1999. e-Pub 1999.
168. Romaguera, J, Khouri IF, Kantarjian HM, Hagemeister FB, Rodriguez MA, McLaughlin P, Sarris AH, Younes A, Rodriguez J, Pate O, Keating MJ, Koller CA, Riggs SA, Champlin R, Cabanillas F. Untreated aggressive mantle cell lymphoma (MCL) presents with frequent gastrointestinal involvment and has high complete response (CR) rates with intensive chemotherapy (IC) without stem cell transplant. Proc Internatl Conf Malig Lymphoma, 1999. e-Pub 1999.
169. Romaguera, JE, Rodriguez MA, Hagemeister FB, McLaughlin P, Rodriguez J, Preti AH, Younes A, Sarris AH, Cabanillas F. Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or resistant or refractory non-Hodgkin's lymphoma (NHL) failing a doxorubicin-containing regimen and a cytarabine/cisplatin-containing regimen. ASH/Blood 94:267b, 1999. e-Pub 1999.
170. Sarris, AH, Hagemeister F, Romaguera J, Rodriguez MA, McLaughlin P, Pate O, Tsimberidou MA, Medeiros LJ, Burge C, Kantarjian H, Cabanillas F. Liposomal vincristine in relapsed NHL: Early results. Proc Internatl Conf Malig Lymphoma, 1999. e-Pub 1999.
171. Sarris, AH, Medeiros LJ, Khorana S, Herling M, Viviani S, Bonfante V, Giardini R, Hagemeister FB, Romaguera J, McLaughlin P, Preti A, Rodriguez MA, Notti P, Ford R, Bonadonna G, Cabanillas F. BCL-2 is frequently expressed in Hodgkin’s Reed Sternberg cells and is associated with inferior failure-free survival in Hodgkin’s disease treated with ABVD. Proc Internatl Conf Malig Lymphoma, 1999. e-Pub 1999.
172. Sarris, AH, Hagemeister FB, Romaguera J, McLaughlin P, Rodriguez MA, Medeiros LJ, Cabanillas F. Primary testicular lymphoma: Is it curable with doxorubicin-based therapy?. ASH/Blood 94:522a, 1999. e-Pub 1999.
173. Sarris, AH, Medeiros LJ, Khorana S, Viviani S, Bonfante V, Nadali G, Hagemeister F, Romaguera J, McLaughlin P, Rodriguez MA, Giardini R, Chilosi M, Ford R, Tsimberidou AM, Gianni M, Bonadonna G, Pizzolo G, Cabanillas F. CD20 in Hodgkin's -Reed-Sternberg (HRS) cells: Association with histologic subtype and progression-free survival (PFS) in Hodgkin's disease (HD). ASH/Blood 94:517a, 1999. e-Pub 1999.
174. Sarris, AH, Romaguera J, Hagemeister F, Rodriguez MA, McLaughlin P, Dang N, Tsimberidou AM, Medeiros LJ, Samuels B, Oholendt M, Pate O, Burge C, Cabanillas F. Liposomal Vincristine: A phase II trial in relapsed or refractory non-Hodgkin's lymphomas (NHL). Proc ASH/Blood 94:94a, 1999. e-Pub 1999.
175. McLaughlin, P, Hagemeister FB, Rodriguez MA, Sarris AH, Cabanillas F, Younes A, Dang N, Romaguera JE. Safety of fludarabine, mitoxantrone, and dexamethasone (FND) + rituximab in the treatment of stage IV indolent lymphoma. ASH/Blood 94:264b, 1999. e-Pub 1999.
176. Tsimberidou, AM, Sarris AH, Medeiros LJ, Mesina O, Hagemeister F, McLaughlin P, Rodriguez MA, Romaguera J, Cabanillas F. Hodgkin's disease in patients infected with HIV: Presentation, frequency and outcome. ASH/Blood 94:527a, 1999. e-Pub 1999.
177. Fayad, L, Rodriguez MA, Rodriguez J, Hagemeister F, Younes A, Sarris A, Romaguera J, McLaughlin P, Cabanillas F. Gallium (67Ga) scan results after second or more cycles of chemotherapy correlates with clinical outcome in aggressive good prognosis (NHL) (AGPNHL) treated with CHOP-containing regimen. Proc ASCO 18:17a, 1999. e-Pub 1999.

Book Chapters

1. Sullivan, TJ, Whitehead, K, Williamson, R, Grimes, D, Schlect, D, Brown, I, Dickie, G, Bhatia, S, Paulino, AC, Buatti, JM, Mayr, NA, Wen, BC, Pinnix, CC, Dabaja, BS, Milgrom, SA, Smith, GL, Abou, Z, Nastoupil, L, Romaguera, JE, Turturro, F, Fowler, N, Fayad, LE, Westin, JR, Neelapu, SS, Fanale, MA, Rodriguez, MA, Hagemeister, FB, Lee, HJ, Oki, Y, Wang, L, Samaniego, F, Chi, L, Esmaeli, B. Orbital adnexal lymphoma, 375-388, 2022.
2. Chihara D, Hagemeister FB, Medeiros LJ, Fanale M. Hodgkin Lymphoma. In: The MD Anderson Manual of Medical Oncology. 3rd. Cenveo, 201-227, 2016.
3. Rios A, Hagemeister FB. AIDS-Related Cancers. In: The MD Anderson Anual of Medical Oncology. 2nd. McGraw-Hill Companies, 1141-1171, 2011.
4. Westin J, Hagemeister F, Fanale M. Hodgkin Lymphoma. In: The MD Anderson Manual of Medical Oncology. 2nd. The McGraw-Hill Companies, 203-243, 2011.
5. Hagemeister FB, Dang NH. Mature T-Cell Non-Hodgkin's Lymphoma: Diagnosis and Therapy. In: Clinical Malignant Hematology. McGraw-Hill, 613-629, 2007.
6. Escalon MP, Hagemeister FB. Aids Related Malignancies. In: M.D. Anderson Manual of Medical Oncology. 1st, 903-935, 2006.
7. Hagemeister FB. Hodgkin's Lymphoma. In: M.D. Anderson Manual of Medical Oncology. 1st, 141-173, 2006.
8. Hagemeister FB. Dysfunction in Patients with Cancer: Definition, Identification, Associations, and Prevention. In: Current Topics in Cancer Quality of Life: Fatigue, Cognitive Dysfunction & Cachexia. Institute for Medical Education and Research, 14-23, 2005.
9. Thomas, DA, Cortez J, Kantarjian HM, Cabanillas F, Hagemeister FB. High Grade Non-Hodgkin’s Lymphomas. In: Malignant Lymphomas. American Cancer Society, 2002.
10. Dwivedy, S, Hagemeister FB. Non-Hodgkin’s Lymphoma. In: Conn's Current Therapy 2001. W.B. Saunders Company, 460-466, 2001.
11. Schulz, C, Hagemeister F, Duvic M. Cutaneous B-cell lymphoma (MALD) associated with Borrelia burgdorferi infection. In: Cutaneous Lymphomas: Unusual Cases. Steinkopff Verlag Darmstadt, 74-75, 2001.
12. Hagemeister FB. Nouvelles voies thérapeutiques. In: Lymphomes non Hodgkin's Biologie-Extranodaux primitifs-Thérapeutique. Arnette Blackwell S.A, 145-150, 1996.
13. Hagemeister FB. Section 5: The blood and spleen. Hodgkin’s Disease: Chemotherapy. In: Conn’s Current Therapy 1992. W.B. Saunders Company, 346-348, 1992.
14. Hagemeister FB. Controversies in Management of Hodgkin’s Disease. In: Therapy of Hematopoietic Neoplasia, Volume 14. Marcel Dekker, Inc, 249-298, 1991.
15. Hagemeister, FB, Fuller LM. Treatment of patients with clinically-staged I and II Hodgkin’s disease. In: Treatment Strategy in Hodgkin’s Disease, Volume 196. John Libbey Eurotext Ltd, 69-71, 1990.
16. Hagemeister, FB, Fuller LM, Martin RG. Staging laparotomy: Findings and applications to treatment decisions. In: Hodgkin’s Disease and Non-Hodgkin’s Lymphomas in Adults and Children. Raven Press, 170-185, 1988.
17. Hagemeister, FB, Fuller LM. Stage III Hodgkin’s disease in adults: Management considerations and results. In: Hodgkin’s Disease and Non-Hodgkin’s Lymphomas in Adults and Children. Raven Press, 230-246, 1988.
18. Hagemeister, FB, Fuller LM. Therapy for stage IV Hodgkin’s disease in adults. In: Hodgkin’s Disease and Non-Hodgkin’s Lymphomas in Adults and Children. Raven Press, 270-283, 1988.
19. Hagemeister FB. Management of relapsing Hodgkin’s disease. In: Hodgkin’s Disease and Non-Hodgkin’s Lymphomas in Adults and Children. Raven Press, 285-302, 1988.
20. Jagannath, S, Armitage JO, Velasquez WS, Hagemeister FB. The role of bone marrow transplantation in the management of Hodgkin’s disease and non-Hodgkin’s lymphomas. In: Hodgkin’s Disease and Non-Hodgkin’s Lymphomas in Adults and Children. Raven Press, 440-450, 1988.
21. Riggs, SA, Hagemeister FB. The clinical and pathologic spectrum of peripheral T cell lymphomas. In: Hodgkin’s Disease and Non-Hodgkin’s Lymphomas in Adults and Children. Raven Press, 381-401, 1988.
22. Riggs, R, Hagemeister FB. Immunodeficiency states: A predisposition to lymphoma. In: Hodgkin’s Disease and Non-Hodgkin’s Lymphomas in Adults and Children. Raven Press, 451-478, 1988.
23. Fuller, LM, Hagemeister FB. Hodgkin’s disease in adults: Stages I and II. In: Hodgkin’s Disease and Non-Hodgkin’s Lymphomas in Adults and Children. Raven Press, 203-229, 1988.
24. Hagemeister, FB, Fuller LM, Velasquez WS, McLaughlin P, Cabanillas F. Two cycles of MOPP as adjuvant therapy for stage I-II Hodgkin’s disease. In: Adjuvant Therapy of Cancer V. Grune & Stratton, 773-781, 1987.
25. Cabanillas, F, Hagemeister FB, McLaughlin P, Velasquez WS. Experience with ifosfamide-based regimens for the treatment of malignant lymphomas. In: Advances in Cancer Chemotherapy: Update on Treatment for Diffuse Large Cell Lymphoma. Park Row Publishers, Inc, 85-89, 1986.
26. Cabanillas, F, Hagemeister FB, Riggs S, Salvador P, Velasquez W, McLaughlin P, Smith T. Results of ifosfamide-Etoposide combinations for patients with recurrent or refractory aggressive lymphoma. In: Malignant Lymphomas and Hodgkin’s Disease: Experimental and Therapeutic Advances. Martinus Nijhoff Publishing, 485-492, 1985.
27. Riggs, SA, Kalter S, Cabanillas F, Hagemeister FB, Velasquez WS, Barlogie B, Salvador P, Mansell P, Hersh E, Butler J. Unusual presentations of non-Hodgkin’s lymphomas in homosexual males. In: Malignant Lymphomas and Hodgkin’s Disease: Experimental and Therapeutic Advances. Martinus Nijhoff Publishing, 261-267, 1985.
28. Spitzer, G, Jagannath S, Dicke K, Zander A, Tannir N, Vellekoop L, Cabanillas F, Hagemeister FB, Velasquez W, McLaughlin P, Verma D. Bone marrow transplantation in lymphoma. In: U. T. M. D. Anderson Clinical Conference on Cancer, Volume 27. Raven Press, 407-425, 1984.
29. Hagemeister, FB, Fuller LM. The use of two MOPP and radiotherapy for the treatment of stages IIIA and IIIB Hodgkin’s disease. In: U. T. M. D. Anderson Clinical Conference on Cancer, Volume 27. Raven Press, 95-106, 1984.
30. Fuller, LM, Hagemeister FB, daCunha M. Treatment of laparotomy-staged I and II Hodgkin’s disease. In: U. T. M. D. Anderson Clinical Conference on Cancer, Volume 27. Raven Press, 71-82, 1984.
31. Velasquez, WS, Jagannath S, Tucker S, Manning J, McLaughlin P, Oh KK, Hagemeister FB, Fuller LM. Prognostic factors for stage III and stage IV diffuse large cell lymphoma: Long-term follow-up. In: U. T. M. D. Anderson Clinical Conference on Cancer, Volume 27. Raven Press, 357-376, 1984.

Letters to the Editor

1. Robbins, WA, Meistrich ML, Moore D, Hagemeister FB, Weier HU, Cassel MJ, Wilson G, Eskenazi B, Wyrobek AJ. Chemotherapy induces transient sex chromosomal and autosomal aneuploidy in human sperm. Nature Genetics 16: 74-78, 1997.